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Riassunto 
Nello sviluppo dei tumori si assiste ad una deregolazione quantitativa 
e/o qualitativa della sintesi proteica. L'espressione delle proteine è 
modulata da diversi processi, come la regolazione di pathway di 
segnalazione ed il controllo di qualità su proteine neo-sintetizzate 
realizzato da chaperoni associati all'apparato traduzionale. In questo 
scenario si inserisce la nostra ricerca focalizzata sullo studio di 
TRAP1, uno chaperone appartenente alla famiglia delle heat shock 
protein 90 e coinvolto nella regolazione della sintesi proteica e nel 
controllo di qualità. Recentemente abbiamo dimostrato che sul 
reticolo endoplasmatico TRAP1 è in grado di legare il proteasoma, i 
ribosomi e i fattori di inizio ed elongazione traduzionale. L'interazione 
con i macchinari di sintesi e degradazione consente allo chaperone di 
modulare co-traduzionalmente l'espressione di due proteine 
mitocondriali codificate dal genoma nucleare che sono più 
ubiquitinate e meno espresse in cellule tumorali silenziate per TRAP1. 
Partendo da queste osservazioni, l'obiettivo della mia tesi di dottorato 
è stato: 
1. caratterizzare il ruolo di TRAP1 nella regolazione della sintesi 
proteica; 
2. identificare i pathway molecolari coinvolti nella regolazione 
traduzionale mediata da TRAP1; 
3. studiare gli effetti della regolazione della sintesi proteica 
mediata da TRAP1 sulla migrazione cellulare. 
I risultati ottenuti hanno confermato l'associazione di TRAP1 
all'apparato traduzionale, essendo lo chaperone associato ai polisomi 
in attiva sintesi. Inoltre, l'incremento di questi ultimi in cellule 
stabilmente silenziate per TRAP1 e l'ottimizzazione della traduzione 
in vitro in seguito all'aggiunta dello chaperone nella reazione, 
conferma il coinvolgimento di TRAP1 nel processo di sintesi proteica. 
In particolare, abbiamo dimostrato che TRAP1 è in grado di favorire 
la sintesi IRES-mediata, mentre attenua quella cap-dipendente. Tale 
attenuazione è controllata indirettamente da TRAP1 attraverso la 
regolazione del pathway AKT/p70S6K. Infatti, sia AKT che p70S6K 
sono meno espresse e meno fosforilate in cellule esprimenti TRAP1 
rispetto alle silenziate. Un aspetto interessante relativo alla 
regolazione di AKT/p70S6K è che le cellule silenziate per TRAP1 
sono dipendenti dalla sitesi proteica e da questo pathway anche nella 
  
migrazione cellulare. Infatti, saggi di migrazione dimostrano che in 
seguito al silenziamento di TRAP1 le cellule sono più veloci rispetto 
al controllo in condizioni basali, mentre rallentano notevolmente in 
seguito a trattamento con inibitori della sintesi proteica ed un inibitore 
specifico di p70S6K. Tali differenze nel comportamento migratorio 
non sono però da attribuire a variazioni del citoscheletro o alla 
riduzione dell'espressione di marcatori epiteliali. Un'analisi di 
espressione genica ha inoltre evidenziato la regolazione di geni 
coinvolti nella motilità cellulare in cellule stabilmente silenziate per 
TRAP1, confermando ulteriormente un ruolo per lo chaperone nel 
fenotipo migratorio. Infine, l'interazione di TRAP1 con il fattore di 
elongazione mitocondriale permette allo chaperone di regolare anche 
la sintesi nel suddetto organello attraverso la modulazione della fase 
di elongazione.  
  
Summary 
Quantitative and/or qualitative protein synthesis deregulation is a 
necessary event to realize and support malignant transformation. 
There are several molecular mechanisms that define the total amount 
of protein expression and assure cell homeostasis, such as signaling 
pathways regulation and a network of ribosome-bound chaperones 
that is involved in a protein quality control exerted on nascent chains. 
Starting from this background our research focuses on TRAP1, a 
member of the heat shock protein 90 family, and on his role in the 
regulation of protein synthesis and quality control. It has been 
previously demonstrated that TRAP1 interacts with a proteasomal 
subunit on the outer side of endoplasmic reticulum, and it has been 
found associated to ribosomes and to initiation/elongation 
translational factors. Then, this interaction with both machineries 
allows TRAP1 to modulate the expression of two mitochondrial 
proteins through a co-translational ubiquitination/degradation. Indeed, 
these two TRAP1 substrates are more ubiquitinated and less expressed 
in cancer cells upon TRAP1 silencing. 
Aims of PhD thesis: 
1. to characterize the role of TRAP1 in protein synthesis 
regulation; 
2. to identify molecular pathways through which TRAP1 
performs this translational modulation in cancer cells; 
3. to study the effects of TRAP1 translational regulation on 
migratory behavior. 
Firstly, we confirmed the association of TRAP1 to the translational 
machinery, since we found that the chaperone associates to 
polysomes. Moreover, an increase of the total amount of active 
polysomes upon TRAP1 silencing and the in vitro translational assays 
evidenced that TRAP1 is involved in protein synthesis process. 
Furthermore, we demonstrated that cap-dependent protein synthesis is 
decreased in presence of TRAP1, whereas the IRES-mediated one is 
enhanced. This attenuation of cap-dependent translation is achieved 
by TRAP1 through and indirect modulation of the expression/activity 
of two PI3K pathway members, AKT and p70S6K. Indeed, these two 
kinases result less expressed and less phosphorylated in TRAP1 
expressing cells compared to TRAP1-knock down cells. A very 
interesting finding is that TRAP1-knock down cells are addicted to 
  
translation and to the AKT/p70S6K axis also for other biological 
processes. Actually, we found that in basal condition TRAP1 silenced 
cells are faster than control cells in migration assays, whereas 
treatments with translational drugs and a p70S6K inhibitor are able to 
abrogate this faster migratory behavior, with scarce effects on control 
cells. Moreover, we excluded that the observed differences are due to 
a cytoskeleton reorganization and epithelial marker downregulation. 
The involvement of TRAP1 in migration regulation was supported by 
a gene expression analysis performed in colorectal cancer cells stably 
interfered for TRAP1, where pro-motility genes were found regulated. 
Finally, as supported by preliminary data/observations, TRAP1 could 
be involved also in mitochondrial protein synthesis regulation, where 
it attenuates translation elongation inhibiting the release of the 
mitochondrial elongation factor from the ribosome.  
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1. Introduction 
 Cancer cells are characterized by a series of hallmarks 
acquired during the complex multistep process of tumor development. 
These include sustained proliferation, evasion from growth 
suppression, acquisition of replicative immortality, resistance to cell 
death, induction of angiogenesis, invasion and metastasis1. Recently, 
metabolic reprogramming and escape from immune destruction have 
been suggested as new hallmarks to add to this previous list1. Among 
those, sustained proliferation, which is an essential part of cancer 
development and progression, is mediated by several mechanisms. 
including a deregulation of mRNAs translation, with an increase of 
overall protein synthesis and selective translation of proteins that 
positively influence cancer progression. Indeed, almost all the 
mentioned tumor hallmarks need a quantitative and/or qualitative 
translation alteration to take place and to be sustained. For example, 
several reports have underlined the translation involvement in cell 
death escape through the aberrant synthesis of “Inhibitor of 
Apoptosis” (IAP) proteins, a family of endogenous caspase inhibitors. 
Cellular stress signals, such as low-dose irradiation, anoxia, serum 
starvation and chemotherapeutic drugs, have been reported to favor 
translation of XIAP or cIAP12. Moreover, Dobson and coworkers3 
have reviewed that the endothelial growth factor (VEGF), an 
angiogenesis inducer, belongs to the proteins upregulated in cancer 
cells thanks specific features present in its 5' untraslated region (5'-
UTR). In agreement with these observations, Yi et al.4 demonstrated 
that HIF-1α up-regulates the eukaryotic initiation factor 4E1, which, 
in turn, promotes VEGF translation in hypoxic breast cancer cells. 
Finally, recent findings revealed how protein synthesis alteration is 
involved in immune system escape strategies. The Programmed death 
1 receptor and its ligand PD-L1 are upregulated on immune cell 
clusters surrounding prostate cancer lesions but not in healthy prostate 
or benign hyperplastic prostate5. Moreover, in glioma as well as in 
trophoblasts, signaling pathway activation correlates with recruitment 
of PD-L1 transcripts to polysomes, leading to increased PD-L1 
translation6. 
Thus, protein synthesis regulation is emerging as a key process in 
cancer cell biology, whose deregulation is required for the onset and 
progression of malignancies. Therefore, it does not surprise that many 
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recent studies suggest therapeutic approaches based on the targeting of 
protein synthesis for the treatment of cancer. 
 
1.1 Cap-dependent and IRES-mediated translational mechanisms 
sustain cancer cells proliferation 
 The most fundamental trait of transformed cells is the 
capability of sustaining chronic proliferation: unlike normal cells, in 
cancer cells the production and release of growth-promoting signals 
are deregulated, making cancer cells masters of their own destinies7. 
Interestingly, they can acquire the capability to sustain proliferative 
signaling in several ways. They can produce growth factor ligands 
themselves, which results in an autocrine proliferative stimulation1, or 
sending signals to normal cells within the tumor-associated stroma, as 
is the case of Transforming Growth Factor β (TGFβ) and Hepatocyte 
growth factor, both involved in the stimulation of fibroblasts, the 
major cellular component of the stroma8. Moreover, cancer cells can 
also increase the levels of receptor proteins at the cancer cell surface, 
such as the epidermal growth factor receptor, whose overexpression 
along with its ligands have been correlated with poor prognosis9. 
Furthermore, a growth factor independence has also been described 
for cancer cells , dependent on the constitutive activation of signaling 
pathways operating downstream of these receptors.  
It is well known that protein synthesis positively correlates with cell 
proliferation rate10 and that upregulated mRNA translation is a 
common feature of pathological states characterized by aberrant 
proliferation, including malignancies. As a consequence, translational 
pathways deregulation is common feature in cancer cells. The 
mechanistic/mammalian target of rapamycin (mTOR) bolsters cell 
proliferation and growth stimulating anabolic processes including 
protein synthesis. Its hyperactivation can be elicited by several 
mutations recently described in cancer10 or by hyperactivation of 
upstream pathways. Indeed, it is well known that the 
PI3K/AKT/mTOR pathway shows gain of function in numerous and 
several human cancers generating signals that have a positive effect 
on the initiation of protein synthesis11. In response to upstream 
signals, PI3K phosphorylates phosphatidylinositol producing 
phosphatidylinositol-3,4-bisphosphate and phosphatidylinositol-3,4,5-
trisphosphate11; these products of PI3K are recognized by the Ser–Thr 
kinase PDK1 that phosphorylates and thereby activates AKT. AKT in 
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turn has numerous protein targets, including pro-apoptotic proteins 
and tumor suppressors, which are downregulated , and growth-
promoting proteins, which are upregulated. Then, the activated 
PI3K/AKT axis activates mTOR that is a sensor of nutrient status, a 
regulator of transcription, and an indirect regulator of protein 
synthesis. This last function is obtained by mTORC1, one of the two 
distinct complexes formed by mTOR, through the phosphorylation of 
4E-binding proteins (4E-BPs), which are negative regulators of 
translation11 and p70S6 kinase (p70S6K), which has 40S S6 ribosomal 
protein as physiological target12. Through their binding to the 
eukaryotic initiation factor 4E (eIF4E), the cap-binding component of 
the translational initiation complex 4F, 4E-BPs are able to prevent 
eIF4E from forming this complex. Phosphorylation of 4E-BPs by 
mTORC1 leads to dissociation from eIF4E that can take part to the 
translational initiation process11, enhancing, in particular, the 
translation of mRNAs with complex secondary structures in their 5'-
UTR regions. Many of these messages code for growth-related 
proteins including growth factors, receptors, kinases, transcriptional 
regulators and cell cycle proteins11. Moreover, translation activation 
causes a positive loop that sustains the translation itself: in fact, 
mTOR-mediated activation of p70S6K enhances translation of 5′ 
terminal oligopyrimidine messages, which code for basic components 
of the translational machinery11. 
Protein synthesis triggered by mTOR signaling pathway represents the 
main mechanism for protein translation in eukaryotic cells. It is called 
cap-dependent translation, a process in which the small ribosomal 
subunit is recruited to the mRNA in a 5′-7-Methylguanosine cap 
proximal position during translation initiation, a process stimulated by 
factors that bind to the cap structure13. In stress conditions, such as 
hypoxia, starvation and response to DNA damage-inducing therapy13, 
and during tumor growth, the cap-dependent mechanism is reduced 
and this event is followed by an increase of the Internal Ribosome 
Entry Site (IRES) translation, in which an IRES element localized in 
5'-UTRs of transcripts that are efficiently translated under stress 
conditions, allows the ribosomal subunits recruitment without a cap13. 
Interestingly, most of the small subset of identified eukaryotic IRESs 
are located in mRNAs encoding, among others, oncogenes, such as c-
MYC, growth factors, such as fibroblast growth factor 2, growth 
factor receptors, such as TrkB, pro- and anti-apoptotic factors, such as 
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XIAP and APAF-1, respectively, and angiogenic factors, such as 
VEGF3. 
Taken together, a general increased protein synthesis and 
overexpression of a specific subset of proteins using specific mRNA 
features and/or different translation mechanisms allow cancer cells to 
increase and sustain their proliferation rate.  
 
1.2 Role of protein synthesis in the EMT program 
 A carcinoma arisen from epithelial tissues progresses to higher 
pathological grades of malignancy, with local invasion and metastasis, 
as well as alteration in the shape and in the attachment to other cells 
and to extracellular matrix (ECM). The molecular mechanism 
involved in invasion and metastasis formation is known as epithelial 
to mesenchimal transition (EMT). This is a biologic process that 
allows a polarized epithelial cell, which normally interacts with 
basement membrane via its basal surface, to undergo multiple 
biochemical changes that enable it to assume a mesenchymal cell 
phenotype. This implicates the acquisition of new features, including 
enhanced migratory capacity, invasiveness, elevated resistance to 
apoptosis, and greatly increased production of ECM components14. 
Master regulators of EMT act on the expression of epithelial and 
mesenchymal markers, such as E-cadherin, a calcium-dependent cell-
cell adhesion molecule, N-cadherin, a transmembrane protein, and 
Vimentin, a major constituent of the intermediate filament family of 
proteins15. The loss of E-cadherin by carcinoma cells represent the 
best characterized EMT hallmark. By forming adherens junctions with 
adjacent epithelial cells, E-cadherin helps to assemble epithelial cell 
sheets and maintain the quiescence of the cells within these sheets. An 
association between E-cadherin loss and invasiveness has been 
established for bladder, renal, endometrial, head, neck, gastric, liver, 
pancreatic and lung cancer16, evidence that strong supports the role of 
E-cadherin as a key suppressor of this metastatic capability. Several 
mechanisms have been implicated in the regulation of E-cadherin 
expression during tumor progression, including genetic, 
transcriptional and epigenetic changes17. Genetic alterations of the E-
cadherin loci are not frequent in tumors, and the majority of 
carcinomas with downregulated E-cadherin maintain an intact E-
cadherin locus. Most transcriptional repressors of E-cadherin have 
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been identified, such as the zinc finger factors Snail and Slug, the two-
handed zinc factors ZEB1 and ZEB2 and the bHLH factor E12/E4717. 
Mechanisms responsible for E-cadherin regulation in most carcinomas 
are mainly represented by epigenetic processes; however, protein 
synthesis also takes part to the EMT program realization. Indeed, 
several of the transcription factors have identified as master regulators 
of EMT are modulated at transcriptional, translational and protein 
stability level by a variety of cell-intrinsic pathways as well as 
extracellular cues18. It has been demonstrated that the activation of 
cap-dependent translation causes cancer epithelial cells to undergo 
EMT, thanks to the upregulation of the EMT inducer Snail which, in 
turn, represses E-cadherin expression, promoting cell migratory and 
invasive capabilities as well as metastasis19. Recent data suggests that 
regulation of gene expression at the posttranscriptional level plays an 
important role in TGFβ-mediated EMT. It has been reported that 
TGFβ binds a region in the 3'-UTR and inhibits the translation of two 
mRNAs mediating EMT, Dab2 and ILEI20. 
Whatever signaling pathways are activated, cell motility is driven 
ultimately by adapted cytoskeletal remodeling. PI3K/AKT/p70S6K 
pathway is involved in this process, also through the translation 
regulation of specific proteins. Indeed, it has been reported that AKT 
is a critical mediator of VEGF-induced endothelial cell migration 
through actin reorganization21; moreover, p70S6K colocalizes with 
actin stress fibers, suggesting that p70S6K activation plays a role in 
actin polymerization12. Finally, an interesting link between translation 
and cell migration is given by the negative effect of rapamycin on this 
phenotype: through the inhibition of mTORC1, rapamycin is in fact 
able to inhibit the synthesis of RhoA, Cdc42, and Rac1, crucial 
regulatory proteins for cell migration. Thus mTORC1-mediated 4E-
BP1 and S6K1 pathways were essential for the expression of these 
small GTPases22. 
 
1.3 Translational machinery and its regulation in cancer cells 
 Translation initiation entails decoding of the AUG start codon 
in mRNA by Methionyl initiator transfer RNA (Met-tRNAi). This 
process is significantly different between eukaryotes and prokaryotes, 
which has profound implications for translational control23. In 
eukaryotes, translation consist of three stages, initiation, elongation 
and termination. 
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1.3.1 Initiation step 
 Translation initiation is the process of assembly of elongation-
competent 80S ribosomes, in which the initiation codon is base-paired 
with the anticodon loop of Met-tRNAi in the ribosomal P-site. This 
process requires at least nine eukaryotic initiation factors (eIFs) and it 
is made up of two steps, the formation of 48S initiation complex, with 
established codon–anticodon base-pairing in the P-site of the 40S 
ribosomal subunit, and the joining of 48S complex with the 60S 
subunit. On most mRNAs, a ‘scanning’ mechanism is required to 
form 48S complex, through which a 43S preinitiation complex 
attaches to the 7-Methylguanosine cap at the 5' end of mRNA. In this 
first step of translation, both the eIF4F complex, containing the 
scaffold protein eIF4G, the DEAD-box helicase eIF4A and the cap-
binding protein eIF4E, and the Polyadenylate-binding protein (PABP) 
play a fundamental role. PABP attaches to both the 3' poly(A) tail and 
eIF4G, and brings the 3' and 5' ends of the mRNA together to form a 
circular mRNA loop24. A stabilization of the complex is achieved by 
an interaction between eIF4B, which binds eIF4A and PABP24. The 
40S ribosomal subunit is recruited to this complex via its interaction 
with eIF3, which in turn binds eIF4G. Met-tRNAi is delivered to the 
40S subunit in the Ternary Complex (TC) with eIF2-GTP23. Then, the 
40S subunit, in cooperation with the TC, eIF1, eIF1A, eIF3, and 
probably eIF5, forms the 43S preinitiation complex . This complex 
can bind the 7-Methyl-guanosine cap and scan the 5′-UTR in the 5′ to 
3′ direction to the initiation codon thanks to the unwinding of the 
mRNA’s 5′ terminal secondary structure operated by eIF4A, eIF4B 
and eIF4F23. Thus, the first AUG encountered is favored as the start 
codon; it enters the ribosomal P-site and base pairs with the anticodon 
of Met-RNAi to form the 48S complex23-24. After initiation codon 
recognition and 48S complex formation, eIF5 and eIF5B promote the 
hydrolysis of eIF2-bound GTP, the displacement of eIFs and the 
joining of a 60S subunit with the formation of the elongation-
competent 80S ribosome, which leads to translation elongation25.  
Because most regulation occurs at the initiation stage of translation, 
the molecular basis of this process is being studied intensively to 
elucidate every potential control points23 and their deregulation in 
cancer. Translation initiation can be regulated through the eIF2α 
phoshorylation and the expression of various initiation factors, and 
through the mTOR signaling pathway and p70S6K expression26. 
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It is well known that rapid responses through the expression of 
specific proteins may allow tumour cells to grow and survive. 
Certainly, translation regulation is a rapid and elegant way of tuning 
gene expression by intensifying protein synthesis from existing 
mRNAs while silencing others, and also saves transcription-related 
energy. A further important mechanism that triggers selective 
translation during the response of cancer cells to stress, including 
hypoxia or chemotherapy, is part of the unfolded protein response 
(UPR) during endoplasmic reticulum (ER) stress21. The main 
mechanism to block cap-dependent protein synthesis is the 
phosphorylation of eIF2α. Upon phosphorylation, the initiation factor 
is fully capable of forming an initiation-competent eIF2-TC, but 
following its release, phosphorylated eIF2–GDP tightly binds to and 
sequesters the guanine nucleotide exchange factor eIF2B, abrogating 
its activity25. There are four mammalian protein kinases that 
phosphorylate eIF2α on Ser51: haeme-regulated kinase, which is 
probably significant only in erythroid cells; PKR, which is activated 
by double-stranded RNAs of more than ~ 40 bp and is important in 
the antiviral response; PKR-like endoplasmic reticulum kinase 
(PERK), which is a transmembrane endoplasmic reticulum enzyme 
with its kinase domain in the cytoplasm, that is activated by ER stress 
(due to misfolded proteins in the ER lumen); GCN2, a homologue of 
the only eIF2 kinase in yeast, which is activated by starvation of 
certain amino acids25. In human cancers, induced eIF2α 
phosphorylation leads to the synthesis of basic leucine-zipper 
transcription factors such as ATF4 and ATF5, which further support 
cancer cell survival21. Preferential activation of eIF2α upregulates 
ATF4 target genes involved in amino acid synthesis and transport as 
well as in response to oxidative or ER stress, and, among others, xCT, 
the specific subunit of cystine/glutamate antiporter system, and 
BiP/Grp78, a major ER chaperone essential for protein quality control 
in the ER27. 
Overexpression of several components of translation initiation 
machinery was shown to cause or to strongly correlate with malignant 
transformation. eIF2α, eIF3a,b,c,h, eIF4A, eIF4G1 and eIF5A have 
been demonstrated to be upregulated in different cancer types13, such 
as melanoma, cervix, breast, testis, prostate, hepatocellular, squamous 
cell lung and ovary cancer, respectively. The cap-binding protein 
eIF4E, the least abundant eIF and hence considered to be a rate 
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limiting factor for cap-dependent translation, is found upregulated in 
bladder, breast, colon, liver, head and neck cancer and non-Hodgkin’s 
lymphoma, and its high expression levels correlate with poor 
prognosis. Interestingly, the upregulation of eIF4E allows to translate 
mRNAs with 5'-UTR normally translated with less efficiency, such as 
many transcription factors, growth factors, receptors and tyrosine 
kinases13. 
As discussed above, the mitogen and nutrient signalling via mTOR, 
which regulates cap-dependent translation through controlling both 
eIF4E and eIF4B via 4E-BP1 and p70S6K respectively28, results 
deregulated in cancer cells causing an upregulation of protein 
synthesis. p70S6K, constitutive activated or amplified and highly 
expressed in cancer cells, positively regulates initiation and elongation 
of translation26. Indeed, p70S6K phosphorylates a negative regulator 
of eIF4A, PDCD4 and targets it for degradation by the ubiquitin 
ligase, βTRCP28. Moreover, this kinase phosphorylates eIF4B on 
Ser422, to enhance the interaction with eIF3. The same authors 
proposed a model in which a pool of inactive p70S6K is bound to 
eIF3. Upon phosphorylation by mTOR, it becomes activated, 
dissociates from eIF3 and phosphorylates its substrates in the pre-
initiation complex, including eIF2B and potentially also PDCD4 and 
the ribosomal protein S628. 
 
1.3.2 Elongation and termination steps 
 The second codon of the open reading frame is present in the 
A-site of the ribosome waiting for the cognate aminoacyl-tRNA 
binding. The eukaryotic elongation factor eEF1A, the orthologue of 
bacterial EF-Tu, binds aminoacyl-tRNA in a GTP-dependent manner 
and then leads the tRNA to the A-site of the ribosome. After codon 
recognition by the tRNA, GTP hydrolysis by eEF1A allows the 
release of the factor and enable the aminoacyl-tRNA to be 
accommodated into the A-site29. The accommodation of the 
aminoacyl-tRNA into the A-site is rapidly followed by the peptide 
bond formation with the P-site peptidyl-tRNA. The peptidyl 
transferase center consisting primarily of conserved ribosomal RNA 
(rRNA) elements on the large ribosomal subunit, positions the 
substrates for catalysis. Following peptide bond formation, ratcheting 
of the ribosomal subunits triggers movement of the tRNAs into so-
called hybrid P/E and A/P states with the acceptor ends of the tRNAs 
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in the E and P-sites and the anticodon loops remaining in the P and A- 
sites, respectively. The elongation factor eEF2, orthologue of bacterial 
EF-G, is then required for the translocation of the tRNAs to the 
canonical E and P sites. Binding of the GTPase eEF2 in complex with 
GTP seems to stabilize the hybrid state and promote rapid hydrolysis 
of GTP. Through conformational changes, eEF2 hydrolyses GTP with 
Pi release and itself is released from ribosome. Moreover, eEF2 seems 
to alternatively unlock the ribosome allowing tRNA and mRNA 
movement and then lock the subunits in the post-translocation state. In 
this state of the ribosome, a deacylated tRNA occupies the E-site and 
the peptidyl-tRNA is in the P-site, whereas the A-site is vacant and 
available for binding of the next aminoacyl-tRNA in complex with 
eEF1A. Recent single molecule and ensemble kinetic analyses 
indicate that release of the E-site tRNA is not strictly coupled to 
binding of aminoacyl-tRNA in the A-site29. 
Although initiation has always been considered the main regulatory 
step of protein synthesis, regulation at elongation is emerging as a key 
checkpoint in cancer, and overexpression of elongation factor has 
been associated to cancer cells. For example, the overexpression of 
EF1A1 and EF1A2 has been found in ovarian and breast cancer30 
respectively. Furthermore, Scaggiante et al31 suggested that eEF1A2 
could be consider a marker for prostate cell transformation and/or 
possibly as a hallmark of cancer progression. Moreover, a role for 
p70S6K in controlling the elongation step of translation was 
demonstrated by the finding that it phosphorylates and inactivates 
eEF2k, which is a Ca2+/calmodulin-dependent protein kinase that 
inhibits the translocation step of elongation phase by phosphorylating 
eEF2 at Thr-5632-33. Interestingly, it has been demonstrated that eEF2k 
has a pivotal role in the adaptation of transformed cells to nutrient 
withdrawal, a capability severely compromised in cells lacking 
eEF2K. Its activity is tightly controlled by nutrient availability 
through direct positive regulation by AMPK and inhibition by 
mTORC1. Therefore, in presence of nutrients, eEF2k is inactive, 
whereas under acute nutrient depletion, tumor cells deal with this 
stress by reactivating the AMPK-eEF2k axis, which confers cell 
survival by blocking translation elongation34. 
Translation termination takes place when the end of the coding 
sequence is reached by the ribosome and a stop codon (UAA, UGA, 
or UAG) enters the A-site. Termination in eukaryotes is catalyzed by 
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two protein factors, eRF1 and eRF3, that appear to collaborate in the 
process29. Whereas eRF1 is responsible for high-fidelity stop codon 
recognition and peptidyl-tRNA hydrolysis and promotes peptide 
release thanks to its middle domain which is functionally analogous to 
the tRNA acceptor stem, the translational GTPase eRF3 is more 
closely related to EF-Tu than to EF-G29.  
 
1.4 The role of ubiquitination and ribosome-bound chaperones in 
protein quality control 
 Every stage in proteins production is under a tight regulatory 
control and it is monitored for errors. All the component of the 
translation machinery undergo a quality control: cells have evolved 
pathways to degrade aberrant mRNAs, to detect mutant or damaged 
rRNAs and ribosomes, and to ensure appropriate tRNA 
aminoacylation35. In addition to the components control, various steps 
during translation are also monitored, through a kinetic proofreading 
during codon-anticodon recognition, and protein quality-control 
pathways that check the folding of nascent polypeptides during and 
after synthesis. Thanks to all these control steps, cells are able to 
detect and remove errors at the earliest chance, instead of giving to the 
polypeptide the opportunity to fold. This opportunity could be useless 
when, for example, a nascent polypeptide on the ribosome can be 
deduced to have a low probability of acquiring a fully functional 
state35. There are several sources that could generate defective 
translation products, such as amino acid misincorporation by 
noncognate aminoacylated tRNAs, defective co-translational protein 
folding, stop codon read-through, and ribosome elongation stalling. 
Sometime, the folding timing itself is a source of errors. In fact, it has 
been demonstrated that often polypeptides emerging from the 
ribosome cannot be completely folding until fully synthesized, 
increasing possibilities of misfolding36. However, it has been 
demonstrated the existence of relatively efficient de novo folding in 
eukaryotic cells, that is performed by an elaborate machinery of 
ribosome-bound chaperones that interacts with and facilitates folding 
of nascent polypeptides36. Unlike bacteria, where the folding of both 
newly synthesized and stress-denatured proteins have been proposed 
to be mechanistically equivalent processes, Albanese et al37 
highlighted the differences between chaperone-mediated de-novo and 
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stress-denatured protein folding in S. cerevisiae. Actually, they refer 
to stress-repressed chaperones associated to translation machinery as 
Chaperones Linked to Protein Synthesis, or CLIPS, and refer to 
chaperones induced by stress as Heat Shock Proteins or HSPs. Thus, 
these two subsets of eukaryotic chaperones have an opposite 
transcriptional regulation in response to stress and act in two different 
environments37. Moreover, the unusual heterodimeric chaperone 
complex termed mammalian ribosome-associated complex38 has been 
identified in higher eukaryotes. This is a conserved eukaryotic 
ribosome-bound protein biogenesis factors, which are dynamically 
interacting factors serving multiple functions, i.e. co-translational 
sorting, folding, and covalent modification of newly synthesized 
polypeptides38. 
When nascent proteins fail to fold, they are targeted to degradation. 
Notably, between 6% and 30% of all eukaryotic newly synthesized 
proteins are very rapidly degraded by the ubiquitin-proteasome system 
(UPS)32. In eukaryotic cells, UPS is the main pathway for elimination 
of misfolded proteins. Polypeptides degradation starts with the E1-E2-
E3 enzyme cascades that marks UPS substrates with ubiquitin; 
subsequently, ubiquitinated polypeptides are delivered to the 26S 
proteasome for degradation32. Indeed, it has been established that co-
translational ubiquitination is a robust component of quality control 
system that marks proteins for destruction while they are being 
synthesized. Moreover, there is an overlap between the machineries 
that carry out quality control on and off the ribosome, since several 
ubiquitin-conjugating enzymes have been demonstrated to participate 
in co-translational process and in a quality control of short lived, 
misfolded proteins36.  
Thus, both chaperone network and ubiquitination system are active 
components of the protein quality control exerted on nascent chains to 
assure a correct folding and an efficient clearance of translation 
defective products. Furthermore, this two control points are linked to 
each other, since co-translational folding provides protection from co-
translational ubiquitination. Indeed, not every polypeptide emerging 
from the ribosome is ubiquitinated co-translationally, but there is a 
subset of nascent chains that is more susceptible to co-translational 
ubiquitination. It has been assessed that rapid translation of proteins, 
that already possess challenging folding properties, i.e. aggregation-
prone sequences, long sequences, are susceptible to co-translational 
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ubiquitination36. Then, the analysis of the nascent polypeptide-
associated complex NAC, a ubiquitously conserved ATP-independent 
heterodimer with a well-defined nascent interactome, suggests that 
this complex protects those nascent chains most susceptible to co-
translational quality control, giving them a chance to prioritize folding 
over degradation as they emerge from the ribosome36. 
 
1.5 TRAP1, Tumor Necrosis Factor receptor-associated protein 1 
 The Tumor Necrosis Factor receptor-associated protein 1 
(TRAP1) is a molecular chaperone that, among the others functions, is 
involved in protein quality control in mammalian cancer cells. Its 
cloning as a type I tumor necrosis factor receptor-associated protein39, 
and its identification as a retinoblastoma-binding protein, were 
independently performed by two different groups40 almost at the same 
moment. TRAP1, also called HSP75, belongs to the HSP90 chaperone 
family41 and shares a 26% identity and 45% similarity with cytosolic 
HSP90. Even if TRAP1 is sufficiently conserved with HSP90, such 
that it is sensitive to the HSP90 inhibitors geldanamycin and radicicol, 
it does not share all the same functions42, suggesting distinct features 
for this protein. TRAP1 has different subcellular localizations with 
distinct functional properties. The attributed cytoplasmic/nuclear 
localizations to TRAP1 by initial works had not been taken in 
consideration for farther studies. On the contrary, the mitochondrial 
localization and the linked functions have been studied for a long 
period, allowing to discover cytoprotective pathways in which TRAP1 
is involved43. Taking advantage from a Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis, in which a lot of 
citoplasmatic proteins were reported as putative TRAP1 partners, in 
2012 our group identified TRAP1 on the outer side of ER and started 
to characterize its functions linked to this new subcellular 
localization44. 
TRAP1 is strictly linked to tumour biology. Actually, it was found 
strongly expressed in tumor cells of adenocarcinomas of pancreas, 
breast, colon, and lung, whereas normal matched epithelia contain 
very low levels of this chaperone45. Moreover, we revealed an 
overexpression of TRAP1 in human colorectal carcinomas, since we 
observed an increased expression in 17/26 tumors46. It was found also 
abundantly and ubiquitously expressed in human high-grade prostatic 
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intraepithelial neoplasia, Gleason grades 3 prostatic adenocarcinomas, 
and metastatic prostate cancer, but largely undetectable in normal 
prostate or benign prostatic hyperplasia in vivo47. Conversely recent 
data present a more complex scenario that requires further insights 
with a lower expression of TRAP1 in lung cancer than in normal lung 
tissue. Similarly, cisplatin-resistant ovarian cancer cells show opposite 
TRAP1 regulation48,49,50. According to its prevalent mitochondrial 
distribution and the great research interest in the characterization of 
TRAP1 mitochondrial functions, the first role assigned to this 
chaperone was the protection against mitochondrial apoptosis51. It has 
been demonstrated that only tumor cells organize a mitochondrial 
chaperone network, which involves HSP90, TRAP1 and the 
immunophilin cyclophilin D in a physical complex that regulates 
permeability transition pore opening, maintaining mitochondrial 
homeostasis and antagonizing the pro-apoptotic function of 
cyclophilin D in permeability transition. Accordingly, inhibition of 
mitochondrial HSP90 chaperones in cancer cells causes sudden loss of 
mitochondrial membrane potential, release of cytochrome c, and 
massive death. TRAP1 involvement in stress-adaptive response of 
cancer cells has been the main interest of our group: high levels of 
both TRAP1 mRNA and protein were found in osteosarcoma cells 
chronically adapted to mild oxidative conditions. Moreover, TRAP1 
has been proposed as the link between resistance to antitumor agents 
and adaptation to oxidative stress, since very high levels of this 
protein were analogously found in tumor cells resistant to 5-
fluorouracil and to platin derivatives. Stable clones expressing 
constitutively high TRAP1 levels are more resistant to H2O2-induced 
DNA damage and to apoptosis by cisplatin, contain higher reduced 
glutathione levels than control cells and do not release the apoptosis-
inducing factor into the nucleus upon cisplatin treatment52. 
Furthermore, TRAP1 hyperexpression causes a decrease of cleaved 
Caspase 3 and PARP, commonly considered as apoptotic markers. 
TRAP1 interference, as well as the use of dominant negative mutants 
of TRAP1, sensitized oxidative stress/chemoresistant cells to cell 
death inducers, thus providing the evidence that TRAP1 is an 
important player in the development and the maintenance of these 
phenotypes53.  
It has been suggested that, through its involvement in protection of 
mitochondria against damaging stimuli via a decrease of Reactve 
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Oxygen Species (ROS) generation, TRAP1 is also involved in cell 
migration and invasion, since ROS are reported to stimulate cell 
invasion54. Moreover, through its capability of downregulating 
mitochondrial respiration and ATP production, TRAP1 knockout or 
transient suppression dramatically enhances cell invasiveness, both in 
mouse fibroblasts and in a variety of human cell lines54. At the same 
time, TRAP1 is a pivotal mediator of tumour cell motility and 
invasion in conditions of nutrient withdrawal: in this view, the 
mitochondrial HSP90, included TRAP1, could allow to overcome the 
global tumour-suppressive network under nutrient deprivation 
allowing cell invasion when it is normally impaired. Accordingly, 
recent studies reported that transient TRAP1 silencing in cancer cells 
was associated with upregulation of a number of cell motility and 
metastasis-associated genes, whereas TRAP1 overexpression was 
correlated with increased expression of genes associated with cell 
proliferation. Beyond metabolic regulations, recent studies proposed a 
link between high TRAP1 expression and increased risk of lymph 
node metastasis in esophageal squamous cell cancer and enhanced cell 
migration and invasion in the same cellular model through the 
STAT3/MMP2 signalling pathway54. 
 
1.5.1 TRAP1 role in protein quality control
 Among the cytoplasmic putative TRAP1-binding partners 
suggested by LC-MS/MS analysis, we found S6/TBP7/ATPase-
4/Rpt3, an ATPase protein of the proteasome regulatory subunit44. 
Thus, we validated this evidence and revealed that TRAP1 and TBP7 
interact on the outer side of ER. Then, our study identified a new 
TRAP1 function linked to this extramitochondrial localization, since 
we demonstrated that its fundamental role in co-translational protein 
quality control and in ER homeostasis. Indeed, we proved that TRAP1 
is involved in quality control of proteins destined to mitochondria. In 
particular, the calcium binding protein Sorcin isoform B and 
F1ATPase β subunit, two nuclear encoded proteins localized in the 
mitochondria, result less expressed and more ubiquitinated in absence 
of TRAP1 in HCT116 cells. This phenotype can be attributed only to 
the extramitochondrial fraction of TRAP1, consistently with the 
absence of proteasomal machinery in the organelle. Moreover, the 
analysis of cellular lysates upon TRAP1 and /or TBP7 interference 
revealed a higher amounts of ubiquitinated proteins than control cells, 
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a phenotype reverted by re-addition of TRAP1 expression vectors. 
The finding that TRAP1 is found associated to ribosomes and to the 
translation factors eIF4A, eEF1A and eEF1G suggested us that this 
quality control on protein expression performed by TRAP1 is co-
translational, thanks to the chaperone simultaneous binding to the 
proteasome and to the translation machinery27. Furthermore, an 
increased expression of Grp78/BiP, the major ER chaperone and 
marker of ER stress conditions, was found upon stress induction, in 
HCT116 cells, in which the expression of TRAP1 was stably knocked 
down by short hairpin RNAs (sh-RNAs). TRAP1 confers to cancer 
cells the capability to cope with stress stimuli through an attenuation 
of global protein synthesis and favoring synthesis of stress-related 
genes. Indeed, we found that the chaperone modulates the eIF2α 
pathway either under basal conditions or under stress, favoring the 
activation of GCN2 and PERK kinases, with consequent 
phosphorylation of eIF2α and attenuation of cap-dependent 
translation. This enhances the synthesis of selective stress-responsive 
proteins, such as the transcription factor ATF4 and its downstream 
effectors BiP/Grp78, and the cystine antiporter system xCT, thereby 
providing protection against ER stress, oxidative damage and nutrient 
deprivation27.  
1.6 Scientific hypothesis and aim of the work 
 Starting from the previous observation of a translational 
attenuation in cancer cells by TRAP1, in the present work we aim to 
shed further light on TRAP1 regulation of protein synthesis and on the 
signaling pathways involved in this process. 
Firstly, the causal role of TRAP1 in translation regulation has been 
analyzed through different approaches. Starting from the hypothesis 
that TRAP1 allows cancer cells to face with limiting/stress conditions 
by favoring translation of stress-related genes, we aim at investigating 
the ability of TRAP1 to cause a switch from cap-dependent to IRES-
mediated translational mechanism. Furthermore, the influence of 
TRAP1 on PI3K pathway will be addressed to understand whether 
this signaling pathway is involved in the attenuation of cap-mediated 
translation by TRAP1 in cancer cells.  
Moreover, some reports have underlined an involvement of TRAP1 in 
cell motility regulation54. Starting from this evidence and considering 
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that a role of PI3K pathway members have been established in cell 
motility, we also wonder if translational regulation by TRAP1 can 
affects cell migration behavior in our cellular system, hypothesizing a 
link between translation regulation and migration. 
Finally, we hypothesize that TRAP1 is able to perform the same 
translational control in mitochondria, since the mitochondrial 
elongation factor EF-Tu, the orthologue of EF1A, was found among 
other putative TRAP1 partners. Therefore, to this aim, we evaluated 
whether and how TRAP1 affects the mitochondrial elongation 
translational step. 
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2. Materials and Methods  
2.1 Cell culture 
 Human HCT116 colon carcinoma cells and HEK293 
embryonic kidney cells were purchased from American Type Culture 
Collection (ATCC) and cultured in McCoy's 5A medium and DMEM, 
respectively. Both culturing mediums contain 10% fetal bovine serum, 
1.5 mmol/L glutamine, penicillin and streptomycin. The authenticity 
of the cell lines was verified 2 year ago by STR profiling, in 
accordance with ATCC product description. TRAP1-stable interfered 
cells were obtained by sh-RNAs as described previously54. 
 
2.2 Plasmid generation and transfection procedures 
 Full-length TRAP1-myc and mutant Δ1-59-myc (both in 
pcDNA 3.1 myc-his vector) were obtained as described in54. pLPL 
Cap- Renilla-IRES-Luciferase bicistronic dual reporter vector was 
kindly donated by Prof. R. Karni, Hebrew University- Hadassah 
Medical School, Jerusalem, Israel and obtained as described in Gerlitz 
et al. (2002). Transient transfection of DNA plasmids was performed 
with the Polyfect Transfection Reagent (Qiagen) according to the 
manufacturer's protocol. TRAP1 transient silencing was performed 
with siRNAs purchased from Qiagen (TRAP1: cat. no. SI00115150). 
For control experiments, cells were transfected with a similar amount 
of scrambled siRNA (Qiagen; cat. no. SI03650318). Transient 
transfections of siRNAs were performed using HiPerFect Transfection 
Reagent (Qiagen) according to the manufacturer's protocol. 
 
2.3 WB/immunoprecipitation analysis  
 Equal amounts of protein from cell lysates and tumour 
specimens were subjected to SDS-PAGE and transferred to a PVDF 
membrane (Millipore). Protein immunoprecipitations were carried out 
as described in54. Where indicated, protein levels were quantified by 
densitometric analysis using the software ImageJ (ref 18 BBA). The 
following antibodies were used for WB, immunofluorescence and 
immunoprecipitation: anti TRAP1 (sc-13557), anti-β-ACTIN (sc-
69879), anti-GAPDH (sc-69778), anti-PI3K (sc-423), anti RSK1 (sc-
231), anti-p70S6K (sc-230), anti-TBP7 (PSMC4 sc-166003), anti-
ERK1 (sc-94) from Santa Cruz Biotechnology; anti-phospho AKT 
(Thr308) (#9275S), anti-AKT (#9272), anti-phospho p70S6K (#9205), 
anti-eIF4G (#2469), anti-eIF4B (#3592), anti-eIF4E (#2067), anti-
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phospho eIF4G (#2441), anti-phospho eIF4B (#3591), anti-phospho 
eIF4E (#9741), from Cell Signaling; anti-E-cadherin (610404) and 
anti-paxillin (6100052) from BD biosciences; phalloidin–
tetramethylrhodamine B isothiocyanate (P1951) from Sigma; and anti-
SNAI1 (GTX100754), anti-TUFM (EF-Tu) (GTX101763) from 
Genetex; anti-phosphoSerine (37430) from Qiagen; anti-rpL11 and 
anti-rpS19 antibodies have been prepared as described in Sulic et al. 
(2005) and in Chiocchetti et al. (2005), respectively. 
 
2.4 RNA extraction and qPCR analysis 
 RNA extraction procedures were performed as described in54. 
The following primers were used for PCR analysis: 18S rRNA 
forward: 5’-GGCGCCCCCTCGATGCTCTTA-3’, reverse: 5’-
GCTCGGGCCTGCTTTGAACAC-3’. The sequences of TRAP1, 
GAPDH, AKT1, AKT2, AKT3, SOX4, PRSS3, F3, E-cadherin and 
Snail primers are reported in54, while sequences of p70S6K and RSK1 
primers are reported in55. When possible, primers were designed to be 
intron-spanning. The reaction conditions were 95 °C for 5 min 
followed by 45 cycles of 15 s at 95 °C and 1 min at 60 °C. GAPDH 
was chosen as the internal control. 
 
2.5 Dual luciferase reporter assay 
 HCT116 cells were transfected using Polyfect transfection 
reagent (Qiagen) with the dual reporter vector pLPL Cap- Renilla-
IRES-Luciferase (Ben-Hur et al., 2013). Cap-dependent translation 
(Renilla luciferase activity) and IRES-mediated translation (Firefly 
luciferase activity) were measured with the Promega Stop and Glo 
assay kit according to the manufacturer’s instructions. 
 
2.6 Ribosome analysis 
 HCT116 or HEK293 cells were collected by scraping and then 
resuspended in lysis buffer. After incubation on ice for 10 min, the 
extract was centrifuged at a maximum speed of 4°C with the 
supernatant (cytoplasmic extract) loaded onto 15 e 50% linear sucrose 
gradient containing 30 mM TriseHCl (pH 7.5), 100 mM NaCl and 10 
mM MgCl2. Gradients were centrifuged for 110 min at 37000 rpm, 
then collected while monitoring the absorbance at 260 nm. In the case 
of protein analysis 1 mL 70% sucrose cushion was added to the 
bottom of the gradient and collected as the first of 12 fractions. All 
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fractions were then precipitated with TCA, resuspended in loading 
buffer and analyzed by WB. The percentage of polysomes has been 
calculated by quantifying the amount of 18S rRNA by qPCR or on the 
basis of the intensities of RPS19 signals. In order to normalize 18S 
rRNA quantification, a known amount of an M7 in vitro synthesized 
RNA has been added to each fraction at the time of collection of 
sucrose gradients and used as a control in qPCR experiments. 
 
2.7 Wound healing assays 
 In order to study the dynamics of wound closure, cells were 
seeded in monolayer by plating in 12-well plates 200,000 cells/well in 
complete medium; 24 h after plating the cell layer was scratched with 
sterile pipette tip. Wound healing was followed for 24 h by acquiring 
digital frames at 10 min intervals. Ribavirin (100 mg/mL), 4EGI-1 (25 
μM), PF4708671 (20 μM), LY294002 (10 μM) were used to pre-treat 
cells for 1 h; Gln deprivation was performed for 16 h before wound. 
Quantitative analysis of wound invasion by cell populations located at 
the border was performed by measuring the gap area at 2 hour 
intervals for 24 h (T0–T24h) using ImageJ. The occupation rate of 
empty space was evaluated as the ratio between average distance 
between the two edges at each time point (Lti) and the same distance 
immediately after the scratch (Lt0). Ribavirin (sc-203238), 4EGI-1 
(sc202597) and PF4708671 (sc-361288) were purchased by Santa 
Cruz Biotechnology; LY294002 (Catalog No 440202), was purchased 
by Calbiochem.  
 
2.8 Confocal microscopy and apoptosis assay 
 sh-TRAP1 and scramble HEK293 or HCT116 cells, plated on 
coverslips, were prepared for immunofluorescence analysis as 
described in54. HCT116 cells were treated with Ribavirin and 4EGI-1 
for 48h. Apoptosis was evaluated as described in27. 
 
2.9 In vitro protein synthesis of eGFP and EmGFP 
 The RTS 100 E. coli HY kit and Wheat Germ extract kit were 
used to synthesize EmGFP and eGFP respectively according to the 
manufacturer's manual.  
 
2.10 Duolink in situ proximity ligation assay 
Materials and Methods 
20 
 
 Duolink in situ proximity ligation assay (Sigma-Aldrich) was 
performed according to the manufacturer’s instructions. 
 
2.11 Stopped-flow FRET assay 
The Cy3-L11 and QSY-EF-Tu were made as described in Liu et al, 
(2014). Initiation complex was made by mixing in WB buffer 70S 
(Cy3-L11), mRNA, prf-fMet, IF1, IF2, IF3 and GTP for 25' at 37°C 
and purified on sucrose cushion. Ternary complex was obtained 
incubating in WB buffer QSY-EF-Tu, yeast Phe, GTP, PEP, PK for 5' 
at 37°C. TRAP1 was pre-incubated with Cy3-70SIC (blue trace) and 
with QSY-TC (purple trace) in two different experiments. The two 
reaction mixtures, with or without TRAP1 were rapidly mixed and 
changes in Cy3-L11 fluorescence were monitored at stopped-flow 
machine. Negative control was obtained using a wild type EF-Tu that 
is unable to quench Cy3 fluorescence. 
 
2.12 Gene expression analysis 
 Gene expression analysis was obtained as described in54. 
 
2.13 Patients 
 Tumour and normal, non-infiltrated peritumoural mucosa were 
obtained from patients with CRC during surgical removal of the 
neoplasm. Samples were prepared for immunoblot analysis. In order 
to compare expression levels of TRAP1 and other proteins (see tables) 
in different tumour specimens, protein levels were quantified by 
densitometric analysis and expressed as time increase/decrease in 
tumours compared to the levels in the respective peritumoural non-
infiltrated mucosa. TRAP1 expression levels were regarded as being 
upregulated if they had increased at least threefold in comparison to 
the corresponding non-infiltrated peritumoural mucosa. 
 
2.14 Statistical analysis 
The χ2 test was used to establish statistical correlation between the 
expression levels of TRAP1 and those of other proteins (see tables) in 
human CRCs. The paired Student t-test was used to establish the 
statistical significance between different levels of gene expression in 
TRAP1 cells compared with related scramble controls. Student t-test 
and ANOVA test were used to establish the statistical significance in 
in vitro translational assays. 
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3. Results 
3.1 TRAP1 associates with and influence the amount of active 
polysomes in cancer cells 
 A physical interaction between co-translationally acting 
chaperones and ribosomes has been widely reported as the primary 
environment for the correct assembling of nascent polypeptides27. 
Consistently, we have already demonstrated that TRAP1 is present in 
the ribosomal fractions purified from HCT116 cells and that it 
interacts with initiation and elongation translational factors27. To have 
further indication on the association of TRAP1 with ribosomes, we 
performed a separation of cytoplasmic extracts from HCT116 cells by 
ultracentrifugation on sucrose gradients. Fractions from the gradient 
were collected and analyzed by western blot (Figure 1a). Results show 
that part of TRAP1 co-sediments with translationally active 
polyribosomal particles, thus supporting the role of TRAP1 in mRNA 
translation. Further evidence for the involvement of TRAP1 in protein 
synthesis was obtained by the analysis of polysome profiles after 
depletion of TRAP1 by RNA interference (sh-TRAP1). As shown in 
Figure 1b, inhibition of TRAP1 expression in both HCT116 and 
HEK293 cells causes an increase in the amount of active polysomes in 
the cell, thereby indicating that the rate of global protein synthesis is 
inversely correlated to TRAP1 expression.  
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Figure 1 TRAP1 co-sediments with polysomes and regulates protein synthesis. a) 
Separation of cytoplasmic extracts from HCT116 cells was performed by ultracentrifugation 
on sucrose gradients as described in Materials andmethods. Proteins from the fractions were 
analyzed by western blot with the indicated antibodies. The absorbance profile in the upper 
panel indicates the sedimentation of the particles: fractions 1 to 7 polysomes; fractions 8 to 10 
monomer (80S) and ribosomal subunits (60S, 40S); fractions 11 and 12 free cytosolic proteins 
or light complexes. b) Absorbance profiles, as in a), of control (scramble) and HCT116 and 
HEK293 sh-TRAP1cells. The percentage of polysomes (indicated in the absorbance profiles) 
is calculated by quantifying the amount of 18S rRNA by qPCR. 
 
3.2 TRAP1involvement in protein synthesis control is confirmed in 
in vitro translation assays 
 To have a clear proof that the direct interaction of TRAP1 with 
translational machinery causes the overall rate change of protein 
synthesis, as already confirmed in this work (Figure 1b), we 
performed in vitro translational assays using Wheat Germ extract. 
Indeed, we analyzed the level of enhanced Green Fluorescence Protein 
(eGFP) mRNA, adding TRAP1 recombinant protein to the reaction. 
As shown in Figure 2, the eGFP protein amount is slightly higher in 
the reaction with TRAP1 compared to the control.  
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Figure 2 TRAP1 is involved in protein synthesis control. eGFP in vitro translation using 
the Wheat Germ extract kit. eGFP mRNA was added to reactions at a final concentration of 
21.95 ng/μL. Where indicated, 0,3 μg/μL TRAP1 recombinant protein was added to the 
reaction. Data are expressed as mean ± SD from 14 independent experiments; *** P≤ 0.0001. 
 
It has been suggested that the role of TRAP1 in protein synthesis 
regulation become essential during cellular stress27. In agreement with 
our previous results, we found that TRAP1 capability of allowing 
translation to adapt and overcome suboptimal conditions is 
highlighted also in in vitro translation experiments. Indeed, we 
observed that, upon reduction of amino acids amount in reactions (20 
fold less than canonical amount), the eGFP protein translation in 
presence of TRAP1 is comparable with the amount obtained in the 
control reaction (containing the canonical amount of amino acids), 
with or without TRAP1. Conversely, amino acids reduction impaired 
eGFP translation in the sample without TRAP1, where a premature 
plateau is achieved (Figure 3). Then, the in vitro translation results 
represent an unequivocal proof of TRAP1 involvement in protein 
synthesis and highlights the capability of TRAP1 of optimizing 
translation and assure it also in limiting conditions. 
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Figure 3 eGFP translation is unaffected by amino acids reduction in presence of TRAP1. 
eGFP in vitro translation using the Wheat Germ extract kit. eGFP mRNA was added to 
reactions at a final concentration of 21.95 ng/μL. Where indicated, amino acids were reduced 
(20 fold) and 0,3 μg/μL TRAP1 recombinant protein was added to the reaction. Data are 
expressed as mean ± SD from 4 independent experiments; * P≤ 0.01; ** P≤ 0.001; *** P≤ 
0.0001. 
 
3.3 TRAP1 regulates cap-dependent and IRES-mediated translation 
mechanisms 
 It is well known that eIF2α phosphorylation attenuates cap-
dependent translation and allows expression of stress responsive genes 
favoring the IRES-mediated translation mechanism, since most of 
these genes have an IRES in their 5'-UTR27. In order to analyze this 
translational switch in our cellular model, we measured the ratio 
between IRES and cap-mediated translation in different experimental 
conditions by transfecting a dual reporter Cap-Renilla-IRES 
Luciferase vector: two translation mechanisms from the same 
transcript were evaluated by assaying the luciferase activity (Figure 
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4). Ratio between IRES- and cap-mediated translation in each 
experimental condition was calculated assuming mean level of 
respective scramble cells equal 1. Results show that the ratio between 
IRES and cap-mediated translation is lower in sh-TRAP1 cells, both 
under basal condition or upon translational stress induced by 
Ribavirin, a translational drug, or Tapsigargin, an ER stress inducer. 
As a control, cells were treated with Cychloheximide, a protein 
synthesis inhibitor. These results clearly point to TRAP1 involvement 
in the attenuation of cap-dependent translation, while favoring the 
IRES dependent one. Although more experiments are needed to affirm 
that this phenotype was predicted by in vitro experiments, we want to 
underline that this result is in agreement with wheat germ extract 
assay, where an mRNA translated by an IRES-mediated mechanism 
was used. 
 
 
 
Figure 4 TRAP1 silencing decreases ratio between IRES- and cap-dependent 
translation. HCT116 sh-TRAP1 and scramble cellswere transfected with pLPL Cap-Renilla-
IRES-Luciferase bicistronic dual reporter vector. As indicated, cells were treated with 
Ribavirin (100 mg/mL) for 16 h, or with Thapsigargin (1 mM) or Cychloheximide (200 
mg/mL) for 6 h. Cap-dependent translation (Renilla luciferase activity) and IRES-mediated 
translation (Firefly luciferase activity) were measured in a dual Luciferase reporter assay 24 h 
after transfection. Graphs represents ratio between IRES- and cap-mediated translation 
calculated assuming mean level of respective control cells (scramble) equal 1. All data are 
expressed as mean ± S.D. from 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001. 
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3.4 TRAP1 attenuates cap-dependent translation by regulating PI3K 
pathway 
 Once demonstrated that TRAP1 down-regulates cap-dependent 
translation in cancer cells, we decided to study the molecular 
pathways modulated by TRAP1 and responsible for this regulation. 
We started to dissect the PI3K pathway, a survival pathway that is 
constitutively activated in many types of cancer and involved in 
regulation of protein translation. Notably, we observed an increased 
expression of AKT upon TRAP1 knock down (TRAP1 KD) in 
HCT116 and HEK293 cells; consequently, phosphorylated AKT 
protein also increased in low TRAP1 background (Figure 5a). 
Conversely, PI3K protein expression levels are not affected by 
TRAP1modulation. Interestingly, immunoblots performed with 
antibody specifically directed against single AKT isoforms show that 
the expressions of AKT2 and AKT3 are the most upregulated upon 
TRAP1 KD, thus contributing to the regulation of total AKT (data not 
shown). To analyze the nature of this regulation, i.e., if TRAP1 
control is at transcriptional/post-transcriptional level, qPCR 
experiments were performed in HCT116 and HEK293 sh-TRAP1 
cells (Figure 5b). Results show that TRAP1 expression does not affect 
single AKT isoform mRNA levels thus suggesting that TRAP1-
dependent control of AKT occurs at post-transcriptional level. Of 
note, the transfection of a myc-tagged TRAP1 construct in both sh-
TRAP1 cells and scramble controls is able to reduce AKT protein 
levels, partially rescuing the original phenotype (Figure 5c); this 
finding further confirms the specificity of TRAP1 role in the 
regulation of AKT expression. Interestingly, the observed effect is 
even higher after transfection of the Δ1-59-TRAP1 deletion mutant, 
which lacks the mitochondrial targeting sequence and is therefore 
unable to enter mitochondria, supporting the evidence that this 
regulation is due to the extramitochondrial-localized TRAP1. 
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Figure 5 TRAP1 regulates AKT expression. a) Total lysates obtained from HCT116 cells 
transfected for 72 h with non targeted control siRNA or TRAP1-directed siRNA and from 
HCT116 and HEK293 sh stable clones were separated by SDS-PAGE and immunoblotted 
with the indicated antibodies. Numbers indicate densitometric band intensities, which have 
been calculated by assuming protein levels of the control equal to 1. Images are representative 
of three independent experiments. b) qPCR analysis of single AKT isoform mRNA 
expression in HCT116 and HEK293 sh-TRAP1 cells. All data are expressed as mean with 
SEM from three independent experiments with technical triplicates each. The p-values 
indicate the statistical significance between relative expression levels. c) HEK293 sh-TRAP1 
and scramble cells were transfected with TRAP1-myc and Δ1-59-myc expression vectors 
(pcDNA 3.1 vector was used as control). Total cell lysates were harvested after 48 h from 
transfection, separated by SDS-PAGE and immunoblotted with the indicated antibodies. 
Numbers indicate densitometric band intensities, which have been calculated by assuming 
protein levels of the control (scramble) equal to 1. Images are representative of 3 independent 
experiments. 
 
p70S6K, a translation regulatory kinase that is downstream AKT and 
is activated by mTORC1, is involved in a positive regulation of cap-
dependent translation through the phosphorylation of rpS6 and 
translation initiation factors. The expression levels of this enzyme was 
analyzed in TRAP1 KD cells vs controls in HCT116 and HEK293 cell 
lines. As shown in Figure 6a this enzyme is hyper-expressed in sh-
TRAP1 cells compared to their scramble controls. Remarkably, also 
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RSK1, another kinase involved in positive translation regulation and 
activated by RAS pathway shows an increased expression upon 
TRAP1 KD (Figure 6a). Interestingly, and likely as a consequence of 
their increased expression, p70S6K and RSK1 show higher 
phosphorylation levels in TRAP1 KD cells compared to controls 
(Figure 6a-b). 
 
 
 
Figure 6 TRAP1 silencing upregulates p70S6K and RSK1 expression/phosphorylation. 
a) HCT116 and HEK293 stable clones total lysates were separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. Numbers indicate densitometric bandintensities, 
eachnormalized to the respective ACTIN band, which have been calculated by assuming 
protein levels of the control (scramble) equal 1 b) HCT116 scramble and sh-TRAP1 cells 
were immunoprecipitated with anti-RSK1 and immunoblotted with anti-phospho-Serine 
antibody. Numbers indicate densitometric bandintensities, eachnormalized to the respective 
total RSK1 immunoprecipitated, which have been calculated by assuming protein levels of 
the control (scramble) equal 1. No Ab, total cellular extracts incubated with A/G plus agarose 
beads without antibody; IP, immunoprecipitation with the corresponding antibody. 
 
Remarkably, TRAP1 expression/function is important for these two 
S6 kinases (S6Ks) regulation: in fact, transient downregulation of 
TRAP1 expression upon siRNA transfection yielded an increase of 
p70S6K and RSK1 protein levels (Figure 7a), findings that 
demonstrate a causal role of TRAP1 for the modulation of 
p70S6K/RSK1 expression. Subsequently qPCR experiments were 
performed to evaluate whether the different expression levels of both 
kinases are due to a transcriptional or post-transcriptional regulation. 
Results showed no differences in their mRNA levels (Figure 7b), thus 
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allowing us to conclude that regulation of p70S6K and RSK1 
expression occurs at post-transcriptional levels. 
 
 
 
Figure 7 TRAP1 regulates p70S6K and RSK1 expression at post-transcriptional level. a) 
HCT116 cells were transfected with non-targeted control siRNA or TRAP1-directed siRNA. 
48 h after transfection, total lysates were harvested, separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. Numbers indicate densitometric band 
intensities, each normalized to the respective ACTIN band, which have been calculated by 
assuming protein levels of the control equal 1. b) qPCR analysis of p70S6K and RSK1 
mRNAs expressionin HCT116 sh-TRAP1 and scramble cells. All data are expressed as mean 
± S.D. from 3 independent experiments. The p-values indicate the statistical significance 
between relative expression levels. 
 
Furthermore, the transfection in HEK293 sh-TRAP-1 cells of 
constructs expressing either a full-length TRAP1 or TRAP1 
mitochondrial-import deletion mutant Δ1-59, is sufficient to 
recapitulate p70S6K protein levels (Figure 8a). While further 
confirming the causal role of TRAP1 in the regulation of p70S6K 
protein expression/ activity, these results demonstrate that regulation 
of protein translation by TRAP1 occurs in an extramitochondrial 
compartment. Moreover, co-immunoprecipitation (co-IP) experiments 
were performed to evaluate whether this regulation is due to a direct 
interaction between TRAP1 and these kinases. Data in Figure 8b 
allow us to conclude that there is no direct binding between TRAP1 
and p70S6K and/or RSK1, whereas the previously well characterized 
interaction between TRAP1 and TBP744 and between RSK1 and 
ERK1/241, used as positive controls of these experiments, could easily 
be detected. All these data suggest that TRAP1 influences this 
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pathway downstream PI3K, through an indirect modulation of AKT 
and p70S6K protein translation. 
 
 
 
Figure 8 TRAP1 modulates p70S6K and RSK1 through an indirect regulation of their 
translation. a) HEK293 sh-TRAP1 and scramble cells were transfected with TRAP1-myc 
and Δ1-59-myc expression vectors (pcDNA 3.1 vector was used as control). Total cell lysates 
were harvested after 24 h from transfection, separated by SDS-PAGE and immunoblotted 
with the indicated antibodies. Numbers indicate densitometric band intensities, each 
normalized to the respective ACTIN band, which have been calculated by assuming protein 
levels of the control (scramble) equal 1. b) Total HCT116 lysates were immunoprecipitated 
with anti-TRAP1, anti-p70S6K and anti-RSK1 antibodies and immunoblotted with indicated 
antibodies. Anti-TBP7 and anti-ERK1/2 were used as positive controls of co-IP. Arrow 
indicates immunoglobulin heavy chains. No Ab, total cellular extracts incubated with A/G 
plus agarose beads without antibody; IP, immunoprecipitation with the corresponding 
antibodies. 
 
Key downstream effectors of S6Ks signaling in protein synthesis 
regulation include several proteins involved in the regulation of cell 
survival upon different stimuli and some translation factors. Among 
others, S6Ks have been shown to impact on the initiation step of 
translation by phosphorylating the cap binding complex component 
eIF4B at serine 42255. Accordingly, we analyzed phosphorylation 
levels of the main translation initiation factors. As represented in 
Figure 9, initiation factors eIF4G, eIF4B and eIF4E show higher 
phosphorylation levels in HCT116 cells with a stable or transient 
TRAP1 KD, whereas their expression levels are unchanged.  
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Figure 9 TRAP1 silencing enhances translation initiation. Total extracts were obtained from HCT116 
stable clones and from HCT116 cells transfected with non-targeted control siRNA or TRAP1-directed 
siRNA for 48 h. Total lysates were separated by SDSPAGE and immunoblotted with the indicated 
antibodies. Numbers indicate densitometric band intensities, each normalized to the respective non 
phosphorylated protein band, which have been calculated by assuming protein levels of the control 
(scramble) equal 1.  
 
3.5 TRAP1 involvement in protein synthesis affects response to 
translational stress and cell migration 
 The role of TRAP1 in the protection against several stress 
types has been extensively described41. However, few data are 
available on the role of TRAP1 in the protection against the 
translational stress. To this aim, we treated cells with the ER-stress 
inducer Thapsigargin to survey stress granules formation in scramble 
vs sh-TRAP1 cells. As shown in Figure 10, Thapsigargin treatment 
induces stress granules in sh-TRAP1 cells. 
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Figure 10 TRAP1 silencing sensitizes cells to translational stress. HEK293 scrambled and sh-TRAP1 
cells were treated with Thapsigargin (Tg) (500 nM) for 50 min. Stress granules were analyzed using 
rabbit monoclonal anti-eIF4G antibody and goat anti-rabbit Alexa Fluor 568. DAPI staining is also shown 
to detect nuclei. 
 
We then selected two drugs inhibitors of mRNA translation, with the 
aim of analyzing the response of control and TRAP1 KD cells: 
Ribavirin, which inhibits cap-mediated translation and 4EGI-1, a 
synthetic peptide that binds the translational initiation factor eIF4E 
and prevents its interaction with eIF4G27. As shown in Figure 11a-b, a 
significant increase in the rate of apoptotic cell death can be observed 
in sh-TRAP1 stable transfectants. Conversely, cells containing higher 
TRAP1 levels seem to be less sensitive, especially for the apoptotic 
response to Ribavirin. The low sensitivity of TRAP1-containing cells 
to blockers of cap-dependent mRNA translation is not surprising, 
considering that an attenuation of protein synthesis is already present 
in these cells. 
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Figure 11 Downregulation of TRAP1 sensitizes cancer cells to drugs targeting cap-dependent 
translation. (a, b) Rates of apoptotic cell death in HCT116 cells treated with Ribavirin (a (100 or 200 
mg/ml) or 4EGI-1 (b (25 or 50 mM) for 48 h upon stable downregulation of TRAP1. All data are 
expressed as mean±S.D. from 3 independent experiments; *P<0.01, **P<0.001, ***P<0.0001. 
 
It has been proposed that agents interfering with the regulatory 
mechanism of gene translation, could be regarding as leading 
compounds in the antimetastatic drug development process27. 
Moreover, few studies suggest an involvement of TRAP1 in the 
regulation of the motile behavior of cancer cells55. Thus, in 
collaboration with the Professor Paolella's group (University of 
Naples), we analyzed the migratory potential of HEK293 scramble 
and sh-TRAP1 cells in the presence/absence of Ribavirin and 4EGI-1, 
in a wound healing assay. In Figure 12, a quantitative analysis as 
linear progression (left) and rate of advancement (right) of the wound 
edge during time is shown. In the reported experiments carried out on 
untreated cells (Figure 12a), TRAP1 interfered cells are faster than 
control cells and completely fill the gap within 16 h; edge 
advancement becomes higher than control cells after the scratch and 
stays higher for several hours, until it is reduced when the wound 
starts to close. Upon Ribavirin treatment (Figure 12b), linear 
progression, as expected, increases in time as long as the wound is 
open and is higher for scramble cells than sh-TRAP1 ones; the rate of 
edge advancement of HEK293 sh-TRAP1 cells is consistently lower 
than scramble cells for most of the observation times, and drops at the 
end, when the effect of wound closure becomes predominant. The 
same effect is observed when the analysis is done by using 4EGI-1 
(Figure 12c). Taken together, the data reveal a role of TRAP1 in 
counteracting the anti-migratory effect of translation inhibitory drugs. 
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Figure12 TRAP1 affects cell migration. Wound healing assay with scrambled and sh-TRAP1 HEK293 
cells. Wound closure, expressed as linear progression (left) and rate of advancement (right) during time 
(see Materials and methods), of scramble (black) and sh-TRAP1 (gray) HEK293 cells a) under control 
conditions andupon treatment with b)100 mg/mL Ribavirin , b) 25 μM 4EGI-1. 
 
To further characterize the molecular environment and players of 
TRAP1 regulation of cell migration, we focused on p70S6K pathway 
and analyzed its involvement in the motility of HEK293 TRAP1 KD 
cells compared to controls. Cell migration has been studied during 
wound healing experiments and quantitatively evaluated in terms of 
occupation rate of empty space. According to our previous results, we 
show that, under basal conditions, sh-TRAP1 cells move faster than 
scramble control; however, treatment with the p70S6K inhibitor 
PF4708671 selectively reduces the rate of edge advancement of 
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HEK293 sh-TRAP1 cells, whereas scramble cells are unaffected. As 
shown in the Figure 13a, the curve for sh-TRAP1 PF4708671-treated 
cells (closed gray symbols) consistently runs above the curve for 
untreated cells (gray curve), whereas the curves for treated and 
untreated scramble cells (black curves) run together. Unlike p70S6K 
inhibition, treatment with LY294002, a PI3K inhibitor, reduces wound 
healing progression of sh-TRAP1 cells and also of scramble cells, 
even if at a lower extent; treatment with LY294002 makes the 
scramble and sh-TRAP1 curves similar, as reported in the Figure 13b 
(see black and gray curves with closed symbols). These findings 
suggest that TRAP1 silencing enhances cell migration by acting 
downstream PI3K through the AKT/p70S6K axis, thus making these 
cells addicted to such pathway. Consistently, sh-TRAP1 cells show 
higher sensitivity to PF4708671 treatment than their scramble 
counterpart, as suggested by reduction of phosphorylation levels of 
the specific p70S6K downstream target eIF4B (Figure 13c), whereas 
PI3K inhibition has the same effect on p70S6K activity in sh-TRAP1 
cells and in control cells (Figure 13d). 
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Figure 13 Effect of PF4708671 and LY294002 on HEK293 scramble and sh-TRAP1 cells during 
wound healing. Wound healing assays of HEK293 cells upon a) PF4708671 and b) LY294002 
treatments. The occupation rate of empty space, evaluated as the ratio between average distance between 
the two edges at each time point (Lti) and the same distance immediately after the scratch (Lt0), is 
reported as a function of time for HEK293 scramble (black) and sh- TRAP1 (grey) cells, by using time 
points corresponding to snapshots taken at 2 hour intervals up to 24 h after the wound. Closed symbols 
are used for cultures in the presence of 20 μM PF4708671 and 10 μM LY294002; simple traces are used 
for untreated cultures. c) and d) HEK293 sh-stable clones were treated with indicated concentrations of 
PF4708671 and LY294002 for 1 h. Total lysates were separated by SDS-PAGE and immunoblotted with 
the indicated antibodies. Images are representative of 3 independent experiments. 
 
3.6 Downstream effects of TRAP1-mediated regulation of 
AKT/p70S6K axis 
 The AKT/p70S6K pathway is considered an important player 
in tumor cell biology, since promote cell cycle progression, cell 
survival, and tumor cell invasion. The latter can be either due to 
cytoskeleton remodelling, induction of epithelial–mesenchymal 
transition, or metabolic reprogramming54. To evaluate whether 
AKT/p70S6K pathway regulation by TRAP1 influences the observed 
cell migratory behaviour through cytoskeleton organization and/or 
focal adhesion expression, we analyzed actin and paxillin distribution 
by immunofluorescence. Results show no differences between 
scramble and sh-TRAP1 cells (Figure 14a-b). The expression levels of 
the two proteins were also observed by immunoblot analysis 
performed in HEK293 stable clones, with comparable results (Figure 
14c). Our data suggest that TRAP1 does not affect actin cytoskeleton 
neither cell–matrix adhesion in our cellular system. 
 
 
 
Figure 14 TRAP1 expression does not influence cytoskeleton organization and paxillin distribution. 
a, b) F-actin and paxillin spikes were visualized in HEK293 scramble and sh-TRAP1 cells by 
immunofluorescence staining. c) HEK293 sh stable clone total lysates were separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. Numbers indicate densitometric band intensities, which 
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have been calculated by assuming protein levels of the control (scramble) equal to 1. Images are 
representative of 3 independent experiments.  
 
Interestingly, it has been shown in ovarian cancer cells that, besides 
AKT, the downstream target p70S6K is directly involved in 
repression of E-cadherin, the transmembrane protein involved in cell 
adhesion, whose downregulation is considered as a hallmark of EMT 
and is typically associated with cancer progression and metastasis54. 
As already explained, p70S6K induction can induce the expression of 
the transcription factor Snail with consequent downregulation of E-
cadherin. Therefore, we questioned whether this pathway is conserved 
in our cellular system and whether the observed differences in cell 
migration are due to E-cadherin expression regulation. qPCR and 
immunoblot analyses (Figure 15a-b) show no changes of Snail mRNA 
and protein levels in HEK293 sh-TRAP1 cells, whereas HCT116 sh-
TRAP1 cells show a slight Snail protein upregulation. Consistently, 
there is no significant change of E-cadherin expression in HCT116 
cells upon TRAP1 KD, as shown by qPCR (Figure 15c), immunoblot 
(Figure 15d) and immunofluorescence (Figure 15e), while a decrease 
of E-cadherin mRNA is observed in HEK293 cells upon both siRNA 
and shRNA-mediated TRAP1 silencing (Figure 15c); however, as 
shown in Figure 15c, HEK293 sh- TRAP1 contain very low level of 
E-cadherin when compared to HCT116 cells, to such an extent to be 
undetectable by immunoblot and immunofluorescence analyses (data 
not shown). These results suggest that the observed effects of TRAP1 
on cell motility are independent from the regulation that the 
AKT/p70S6K axis exerts on actin cytoskeleton dynamics and EMT; 
however, although a possible role of AKT in EMT program upon 
TRAP1 KD is supported by E-cadherin modulation in HEK293 cells, 
these findings require further study in cell models in which the role of 
the AKT/p70S6K pathway in the EMT program has already been 
assessed. 
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Figure 15 Correlation between TRAP1 and Snail gene expression and effects of AKT/p70S6K 
pathway on E-cadherin expression. a) qPCR analysis of Snail mRNA expression in HCT116 and 
HEK293 sh stable clones. All data are expressed as mean with SEM from 3 independent experiments 
with technical triplicates each. The p-values indicate the statistical significance between relative 
expression levels. Dashed line indicates expression level of scramble controls. b) HCT116 and HEK293 
sh stable clone total lysates were separated by SDSPAGE and immunoblotted with the indicated 
antibodies. Numbers indicate densitometric band intensities, which have been calculated by assuming 
protein levels of the control (scramble) equal to 1. c) qPCR analysis of E-cadherin mRNA expression in 
HEK293 sh stable clones and siRNA-mediated TRAP1 interfered HEK293 and HCT116 cells, harvested 
96 h after transfection. All data are expressed as mean with SEM from 3 independent experiments with 
technical triplicates each. The p-values indicate the statistical significance between relative expression 
levels. Dashed line, dark grey line and light grey line indicate reference expression levels of the scramble 
controls for HCT116 siTRAP1, HEK293 siTRAP1 and HEK293 sh-TRAP1 respectively. d) HCT116 sh 
stable clone total lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. 
Numbers indicate densitometric band intensities, which have been calculated by assuming protein levels 
of the control (scramble) equal to 1. e) Confocal microscopy analysis of E-cadherin in scramble and sh-
TRAP1 HCT116. All images are representative of 3 independent experiments. 
 
To complete our analysis of possible mechanisms involved in TRAP1 
control of cell migration, we focused on the regulation of metabolic 
processes by TRAP1 and analyzed their correlation with cell 
migration. To this aim, we withdraw from culture medium glutamine 
(Gln), which is an important biosynthetic amino acid source, 
especially in cells with high energy demands for the synthesis of large 
amounts of proteins and nucleic acids. The results of these 
experiments show that Gln removal causes a reduction of cell motility, 
with effects being particularly significant in TRAP1 KD cells (Figure 
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16a). This abolishes the increased cell migration observed upon 
TRAP1 KD under basal conditions. Consistently, Gln deprivation 
reduces phosphorylation of p70S6K (Figure 16b), compromising cell 
motility in TRAP1 KD, addicted to the p70S6K pathway. Taken 
together, these results suggest that TRAP1 is an important regulator of 
AKT/p70S6K activity, through the regulation of their expression; this, 
in turn, confers resistance to nutrient deprivation and to p70S6K 
inhibitory drugs, thus enabling cell motility under condition in which 
it would be normally impaired. 
 
 
 
Figure16 Effect of glutamine deprivation on scramble and sh-TRAP1 cells in wound healing assay. 
a) Wound healing assays of HEK293 cells upon Gln deprivation: the occupation rate of empty space, 
evaluated as the ratio between average distance between the two edges at each time point (Lti) and the 
same distance immediately after the scratch (Lt0), is reported as a function of time for HEK293 scramble 
(black) and sh-TRAP1 (gray) cells by using time points corresponding to snapshots taken at 2 hour 
intervals up to 24 h after the wound. Closed symbols are used for glutamine-deprived cultures; simple 
traces are used for untreated cultures. b) HEK293 sh stable clones were cultured in a Gln. Total lysates 
were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Images are 
representative of 2 independent experiments. 
 
3.7 TRAP1 regulates genes involved in cell movement and 
metastases 
 To further evaluate the influence of TRAP1 on the migratory 
phenotype, we took advantage of a whole genome gene expression 
profiling recently performed in HCT116 sh-TRAP1 cells (Array 
Express, accession number E-MTAB-2500). This allowed the 
identification of 504 genes significantly modulated in TRAP1-
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silenced cells (p<0.001), with 246 up- and 258 downregulated. The 
analysis of the dataset with the Ingenuity Pathway Analysis identified 
cell movement among the top 5 predicted biofunctions. Among all the 
genes associated with cell movement, 3 of them, SOX4, F3 and 
PRSS3, have a cutoff value of fold change >3. The expression of the 
three genes was validated by qPCR, and SOX4 and F3 confirmed their 
transcriptional regulation in HCT116 upon TRAP1 interference 
(Figure 17). Among those, the regulation of F3/Tissue Factor, a gene 
playing an important role in tissue repair, inflammation, angiogenesis, 
and tumour metastasis54, was also confirmed in HEK293 cells, in 
which TRAP1 downregulation yields a significant decrease in F3 
mRNA levels. 
 
 
 
Figure 17 TRAP1 expression modulates genes involved in cell movement. qPCR analysis of SOX4, 
F3 and PRSS3 mRNA expression in HCT116 and HEK293 TRAP1 stably interfered clones. All data are 
expressed as mean with SEM from 3 independent experiments with technical triplicates each. The p-
values indicate the statistical significance between relative expression levels. Dashed line indicates 
expression level of scramble controls. 
 
3.8 The role of TRAP1 in protein synthesis is relevant in cancer 
 Finally, we evaluated whether TRAP1-dependent regulation of 
protein synthesis rate and of AKT/p70S6K axis may be relevant in 
human colorectal cancer (CRC). 
We used a tissue collection of CRCs and analyzed 10 TRAP1-positive 
and 10 TRAP1-negative human CRCs for eEF1G, eEF1A, eIF4A and 
eIF4E expression. Remarkably, the majority of the TRAP1-positive 
tumors exhibited upregulation of eEF1G (7/10 cases), eEF1A (8/10), 
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eIF4A (5/10 cases) and eIF4E (8/10 cases). In contrast, among 10 
tumors with low expression of TRAP1, all exhibited low levels of 
eIF4A and eIF4E, 9/10 exhibited low expression of eEF1G and 7/10 
exhibited low expression of eEF1A. A χ2 test demonstrated a positive 
statistical correlation between the expression levels of TRAP1 and 
those of eEF1G (P=0.02), eIF4A (P=0.039) and eIF4E (P=0.001) and 
a trend toward a positive correlation between TRAP1 and eEF1A 
levels (P=0.07) (Table 1). 
Moreover, a correlation between TRAP1 and AKT/phospho-AKT and 
a correlation between TRAP1 and p70S6K/phospho-p70S6K levels 
were confirmed in our CRC collection. Table 2 reports the 
immunoblot densitometric analysis of AKT and phospho-AKT in 14 
tumour samples, where the majority of TRAP1-upregulated tumours 
exhibited the downregulation of AKT (10/14 cases). Phosphorylation 
levels were also assessed, with 12/14 TRAP1-upregulated tumours 
exhibiting the downregulation of phospho-AKT, as confirmed by the 
χ2 test (p<0.01).  
The majority of TRAP1-upregulated tumors exhibited the 
downregulation of p70S6K (12/17 cases), as confirmed by the χ2 test 
(p=0.04); phosphorylation levels were also assessed, with similar 
results, as reported in Table 3. By contrast, tumors with non 
upregulated TRAP1 levels showed stable or upregulated levels of 
p70S6K and phospho-p70S6K. 
Taken together, these observations suggest that TRAP1-dependent 
regulation of AKT/p70S6K axis and, likely, its downstream pathway, 
is conserved in human colorectal tumors with high TRAP1 
expression. 
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3.9 TRAP1 exerts control on protein synthesis also in mitochondria 
The mitochondrial EF-Tu (mEF-Tu), the orthologue of EF1A, is a 
putative partner of TRAP1 in our LC-MS/MS analysis. Starting from 
this evidence, we wondered whether TRAP1 controls protein 
synthesis also in mitochondria, the most TRAP1-enriched organelle. 
Interestingly, a duolink in situ proximity ligation assay and a 
microscopy analysis showed that TRAP1 binds mEF-Tu and both 
colocalize in mitochondria (Figure 18a-b). Since the mitochondrial 
and prokaryotic EF-Tu shares a 55-60% of identity, we took 
advantage from prokaryotic tools to further investigate this 
interaction. Preliminary data obtained using an E.coli cell-free system 
for in vitro transcription/translation of GFP variant Emerald (EmGFP) 
(Figure 18c) show that TRAP1 is able to influence prokaryotic protein 
synthesis, as already observed in wheat germ extract assays.  
Table 1 TRAP1 regulation of 
protein synthesis in CRCs. 
Table 3 Inverse 
correlation between 
TRAP1 and p70S6K 
expression and 
phosphorylation.  
Table 2 Inverse 
correlation between 
TRAP1 and AKT 
expression and 
phosphorylation 
Results 
43 
 
 
C
TR
L
TR
A
P
1
80
100
120
140
160
*
R
e
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 
Figure 18 TRAP1 is involved in mitochondrial protein synthesis through its interaction with mEF-
Tu. a) Duolink in situ proximity ligation assay imaging were obtained by incubating cells with primary 
antibodies, with secondary antibodies conjugated with MINUS and PLUS oligonucleotides, followed by a 
ligation and amplification reaction. Proximity ligation assay dots (red) are generated if two proteins are in 
close proximity (<40 nm). b) TRAP1/mEF-Tu colocalization: HCT116 cells were fixed and treated as 
described in Materials and Methods. c) EmGFP in vitro transcription/translation using E. coli lysates. 
EmGFP expressing vector was added to reactions at a final concentration of 10 ng/μL. Where indicated 
0,2 μg/μL TRAP1 recombinant protein was added to the reaction. Data are expressed as mean ± SD from 
6 independent experiments; * P≤ 0.01. 
 
To further investigate whether TRAP1/EF-Tu interaction could affect 
the activity of the elongation factor, we analyzed the association and 
dissociation of prokaryotic EF-Tu from the ribosome by stopped-flow 
experiments. A Ternary Complex in which EF-Tu is labeled with the 
QSY9 fluorescence quencher (QSY-TC), and a bacterial 70S Initiation 
Complex labeled with a Cy3 fluorophore on protein L11 (Cy3-
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70SIC), have been used in these assays. Upon entering in the A-site, 
the quencher-labeled EF-Tu decreases the Cy3–labeled ribosome 
fluorescence, whereas its dissociation from the ribosome allows Cy3 
fluorescence recovery. As shown in Figure 19, TRAP1 is able to 
inhibit dissociation of prokaryotic EF-Tu from 70SIC, and this is more 
evident upon TRAP1 and QSY-TC preincubation (purple trace). 
 
 
 
Figure 19 TRAP1 inhibits EF-Tu release from 70SIC. Stopped-flow assays: 0,3 μg/μlTRAP1 
recombinant protein was pre-incubated with QSY-TC (purple trace) or with Cy3-70SIC (blu trace); upon 
a rapid mixing of the two mixtures, change in Cy3 fluorescence was monitored using a stopped-flow 
instrument (see Material and Methods). Black trace, negative control; red trace, positive control  
 
All together these preliminary results suggest that TRAP1 could 
attenuate mitochondrial protein translation through a direct inhibition 
of elongation step.  
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4. Discussion/Conclusions 
TRAP1 is upregulated in most tumor types and it is involved in the 
protection from oxidative stress and mitochondrial cell death, in 
signaling circuitries of mitochondrial integrity and cellular 
homeostasis27. Recently, we have shown that TRAP1 is involved in 
the crosstalk between mitochondria and ER and in ER stress 
protection of tumor cells: indeed, we demonstrated a role of TRAP1 in 
protein quality control due to its interaction with proteasomal and 
translational machinery components in the ER27,44. The association of 
the chaperone apparatus to protein synthesis machinery has been 
already demonstrated in eukaryotic system as well as the contribute of 
ribosome-bound molecular chaperones in the protection of nascent 
chains from premature co-translational ubiquitination27. We found 
TRAP1 associates with polysomes in cancer cells; moreover, we 
observed a change in the total amount of active polysomes upon 
TRAP1 inhibition, highlighting that this interaction to translational 
components has more implications than the classical de novo protein 
folding already described for chaperones. Consistently, the in vitro 
translation assays clearly confirm TRAP1 causal role in protein 
synthesis attenuation. The optimization of protein synthesis in in vitro 
translational assays using both wheat germ and E.coli extracts could 
be considered as an unequivocal proof of TRAP1 influence on 
translational components. Further in vitro experiments by using 
eukaryotic translational tools and an mRNA translated by a cap-
mediated mechanism could allow us to determine if this in vitro assay 
may provide more information, such as a prediction of cellular 
phenotype. 
A very interesting finding in the present work is the identification of a 
new cytoprotective role carried out by TRAP1: through regulation of 
protein synthesis, TRAP1 confers cells the capability to cope with 
stresses, therapy-induced or normally found in tumour 
microenvironment. Indeed, it is well known that the post-
transcriptional regulation represents a fast way to handle stress 
stimuli: it is clear that in such situations the usual order of events, with 
transcription and subsequent translation, may be too slow for an 
appropriate physiological reaction56. Thus, the concept of "translation 
on demand" has been proposed as the mechanism to characterize the 
responses of tumor cells in different biological phenotypes54. This 
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scenario involves, among others, a sophisticate and intertwined 
regulation of cap/IRES-dependent translational control, allowing for 
continued translation in the presence of cellular stresses that reduce 
cap-dependent translation. We demonstrated that TRAP1 is involved 
in the attenuation of cap-dependent synthesis, suggesting that this 
translational control mechanism would provide a survival advantage 
to cancer cells, expanding indefinitely their growth even under 
unfavorable conditions. Moreover, this is in agreement with 
demonstration that high rates of translation elongation negatively 
affect both the fidelity of translation and the co-translational folding 
of nascent polypeptides. As a consequence, by slowing down 
translation, cancer cells can efficiently improve the correct folding of 
proteins relevant for tumorigenesis. Furthermore, we show a change in 
the balance between cap and IRES dependent translation in the 
presence of TRAP1, leading to an attenuation of cap-dependent 
translation, favoring IRES-dependent one. This mechanism is relevant 
in cancer development, because among 70 experimentally verified 
cellular IRES elements, a large number are found in cancer related 
genes55. 
The importance of this regulation in tumour biology, led us to further 
analyze the pathways of protein synthesis in cancer cells regulated by 
TRAP1. Then, we show that expression and consequent 
phosphorylation of p70S6K and RSK1, two translation activating 
kinases, are increased in TRAP1 KD cells and that the regulation of 
p70S6K and RSK1 expression occurs at post-transcriptional levels. 
S6Ks have been shown to accelerate the initiation step of translation 
by phosphorylating the cap binding complex component eIF4B at 
serine 42255. Consistently, we show that phosphorylation levels of 
translation initiation factors, namely eIF4G, eIF4B and eIF4E, are 
higher in colorectal cancer cells upon TRAP1 KD, thus indicating a 
condition of improved cap-dependent translation. Remarkably, we 
have unveiled a link between translational stress response and cell 
migration behavior, both processes in which TRAP1-regulated S6Ks 
are involved54. The wound healing assays in the presence and absence 
of translational drugs, such as Ribavirin and 4EGI-1, show that 
TRAP1 influences global mRNA translation and favors the synthesis 
of pro-motility molecules, as also revealed by the gene expression 
performed in HCT116 stable clones, thus allowing migration under 
conditions where cell migration is normally impaired. Moreover, 
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lower TRAP1 background makes cancer cells more dependent from 
protein synthesis, as demonstrated by apoptosis increase in sh-TRAP1 
cells upon Ribavirin and 4EGI-1 treatments. Notably, the role of 
TRAP1 in promotility/metastatic phenotypes is still an open issue. In 
fact, it should be mentioned that opposite effects on cell 
migration/invasion on compromising TRAP1 function have been 
observed, likely reflecting the altered metabolic environment found in 
diverse tumor types examined under distinct conditions54. Although 
all reports agree that TRAP1 has important implications for neoplastic 
progression, data from the different groups only partially overlap, 
suggesting that TRAP1 may have complex and possibly contextual 
effects on tumorigenesis54. We have also demonstrated that TRAP1 
affects cell migration through a regulation of the AKT/p70S6K axis, 
which is upregulated in TRAP1 KD cells. As a consequence, upon 
TRAP1 silencing cancer cells show a higher migratory potential under 
condition of full nutrient availability and in the absence of cellular 
stress, whereas in low TRAP1 background, cells seem to be addicted 
to the activation of this pathway, as demonstrated by stronger 
inhibition of cell migration in sh-TRAP1 cells upon treatment with 
PF4708671, a p70S6K inhibitor. Analogously, glutamine deprivation 
profoundly affects the ability of cells to migrate in low TRAP1 
background, whereas motility of TRAP1 expressing cells is 
marginally impaired. The observed high motile behavior in low 
TRAP1 background is therefore p70S6K- and glutamine-dependent. 
Accordingly, Caino et al57. showed that mitochondrial HSP90s, 
including TRAP1, are crucial for tumour cell motility in condition of 
poor nutrient availability. Moreover, in the absence of metabolic 
stress, cells most rely on AKT/p70S6K pathway for cell motility. 
Interestingly, it has been shown that cells expressing constitutively 
active AKT are highly sensitized to cell death induced by nutrient and 
growth factor deprivation54. In this view, TRAP1 expression could 
represent a mechanism of resistance adopted by cancer cells when 
nutrient scarcity requires downregulation of the AKT pathway.  
According to the classical multistep model, metastases generated from 
tumour cells that are able to infiltrate vessels, survive to circulation in 
the blood stream and colonize new sites. To do this, cells must 
undergo several morphologic and metabolic changes that go under the 
definition of epithelial to mesenchymal transition. In this context, it 
has been reported that p70S6K is involved in the regulation of the 
Discussion 
48 
 
Snail gene54. We have therefore analyzed the expression of Snail and 
E-cadherin in two different cell models, finding that a slight regulation 
in the expression of both genes is detectable upon TRAP1 KD, 
although this seems not to be the main mechanism responsible for the 
changes in the motile behavior of these cells. Conversely, we 
demonstrated, at least in our experimental systems, a prevalent 
function of metabolic balance for the TRAP1-dependent regulation of 
the AKT/p70S6K pathway. Possibly, more suitable experimental 
systems, in which many data already confirmed the causal correlation 
between cell migration, EMT and the PI3K/AKT/p70S6K pathway, 
will provide further insights into TRAP1 role in metastatic 
dissemination. Of note, it has been demonstrated54 that in two 
different cell lines the expression of TRAP1 is inversely related to the 
expression of genes involved in metastasis, suggesting that, while 
induction of TRAP1 expression promotes cell proliferation and 
tumour growth through the TNF pathway, its downregulation may 
lead to decreased proliferation and increase of metastatic potential. 
We also analyzed the gene expression pattern of HCT116 cells 
following TRAP1 downregulation, and found several genes involved 
in cell motility and EMT to be differentially regulated in TRAP1 KD 
cells. In particular, we have analyzed the expression of SOX4, F3 and 
PRSS3. SOX4, which is considered the master regulator of EMT54, is 
substantially upregulated in HCT116 sh-TRAP1 cells. SOX4 KD has 
been related to reduced tumour cell migration, invasion, in vivo 
tumourigenesis and metastasis in hepatocellular carcinoma54, and 
overexpression of nuclear SOX4 was significantly correlated with 
invasion, metastasis and stage in CRC patients54. Conversely, we 
found that the F3/Tissue Factor gene, which has a role not only in 
coagulation control, but also in angiogenesis54, is two-fold 
downregulated in the highly motile sh-TRAP1 cells. Interestingly, F3 
is the only gene that we have found significantly downregulated in 
both cell lines in which TRAP1 has been silenced. Taken together, 
these results confirm a dual role of TRAP1 in the regulation of cell 
motility, enabling cell movement under limiting conditions, while 
possibly reducing the maximum migratory potential of cells when 
plenty of energy source are available. 
The regulation of protein synthesis and AKT/p70S6K axis is 
conserved in CRC specimens; moreover, our preliminary observation 
shows high tendency of TRAP1-positive CRCs to produce distant 
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metastases, despite low AKT expression. This data suggest that 
TRAP1 has a pivotal role in CRC development and migration, and 
underline that this chaperone is an important element in the multistep 
process of tumor progression and metastasis dissemination. Hence, 
targeting TRAP1 may enhance the efficacy of antimetastatic 
treatments selectively for those cancers in which signaling pathway by 
this chaperone contributes to resistance to tumour-suppressive 
mechanisms and metabolic stress. 
TRAP1 role in protein synthesis control has left some open questions. 
Whereas the regulation of AKT/p70S6K pathway has been 
extensively analyzed, it is possible that TRAP1 is able to inhibit a 
translational step by its direct interaction with initiation and 
elongation factors. Our preliminary data show that TRAP1 binds the 
mitochondrial EF-Tu, the counterpart of the cytosolic EF1A. Taking 
advantage from sequence identity (more than 50%) between the 
mitochondrial and the prokaryotic EF-Tu, we demonstrated that 
TRAP1 inhibits the elongation factor release from the prokaryotic 
ribosome, slowing down the elongation step. A similar regulation of 
EF1A factor has been reported in several papers. Sivan et al58 
demonstrated that, during mitosis, the elongation step is regulated 
through the phosphorylation of eEF1B, a factor necessary to catalyze 
the GDP /GTP exchange on eEF1A, that causes a lower affinity to its 
substrate. This modification is correlated with reduced availability of 
eEF1A-tRNA complexes, as well as reduced delivery of tRNA to and 
association of eEF1A with elongating ribosomes. Moreover, Howe et 
al20 identified the eukaryotic EF1A1 as an integral component of a 
complex that binds to a structural element in the 3′-UTR of two 
mRNAs inhibiting their translation. A component of this complex 
blocks progression of the 80S ribosome by preventing the release of 
eEF1A1 from the ribosomal A site post GTP hydrolysis. We have 
hypothesized that TRAP1 could directly affect the release of EF-Tu 
from ribosome, since the stopped-flow reaction composition allows to 
observe only one round of bound/release of the elongation factor from 
the ribosome, excluding a recycling of EF-Tu. However, further 
studies are needed to clarify which step of elongation stage is affected 
by TRAP1, i.e. GTP hydrolysis, EF-Tu-GDP dissociation from the 
ribosome, and to understand if EF1A undergos a similar regulation.  
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Translational control in the stress adaptive response
of cancer cells: a novel role for the heat shock protein
TRAP1
DS Matassa1, MR Amoroso1, I Agliarulo1, F Maddalena2, L Sisinni2, S Paladino1,3, S Romano1, MF Romano1, V Sagar4, F Loreni4,
M Landriscina*,5 and F Esposito*,1
TNF receptor-associated protein 1 (TRAP1), the main mitochondrial member of the heat shock protein (HSP) 90 family, is induced
in most tumor types and is involved in the regulation of proteostasis in the mitochondria of tumor cells through the control of
folding and stability of selective proteins, such as Cyclophilin D and Sorcin. Notably, we have recently demonstrated that TRAP1
also interacts with the regulatory protein particle TBP7 in the endoplasmic reticulum (ER), where it is involved in a further extra-
mitochondrial quality control of nuclear-encoded mitochondrial proteins through the regulation of their ubiquitination/
degradation. Here we show that TRAP1 is involved in the translational control of cancer cells through an attenuation of global
protein synthesis, as evidenced by an inverse correlation between TRAP1 expression and ubiquitination/degradation of nascent
stress-protective client proteins. This study demonstrates for the first time that TRAP1 is associated with ribosomes and with
several translation factors in colon carcinoma cells and, remarkably, is found co-upregulated with some components of the
translational apparatus (eIF4A, eIF4E, eEF1A and eEF1G) in human colorectal cancers, with potential new opportunities for
therapeutic intervention in humans. Moreover, TRAP1 regulates the rate of protein synthesis through the eIF2a pathway either
under basal conditions or under stress, favoring the activation of GCN2 and PERK kinases, with consequent phosphorylation of
eIF2a and attenuation of cap-dependent translation. This enhances the synthesis of selective stress-responsive proteins, such
as the transcription factor ATF4 and its downstream effectors BiP/Grp78, and the cystine antiporter system xCT, thereby
providing protection against ER stress, oxidative damage and nutrient deprivation. Accordingly, TRAP1 silencing sensitizes
cells to apoptosis induced by novel antitumoral drugs that inhibit cap-dependent translation, such as ribavirin or 4EGI-1, and
reduces the ability of cells to migrate through the pores of transwell filters. These new findings target the TRAP1 network in the
development of novel anti-cancer strategies.
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TNF receptor-associated protein 1 (TRAP1), the only mito-
chondrial member of the heat shock protein (HSP)90 protein
family, is involved in protection from oxidative stress and
apoptosis induced by several antitumor agents and other
stressors.1 Acute silencing of TRAP1 in tumor cells has been
consistently associated with CypD-dependent mitochondrial
apoptosis.2 TRAP1-dependent organelle-directed regulation
of folding and stability of selective proteins involved in
mitochondrial homeostasis, such as Cyclophilin D and Sorcin,
is pivotal for the control of tumor cell proteostasis, leading to
resistance to apoptosis.3 Remarkably, aberrant deregulation
of TRAP1 function has been observed in colorectal4 and
prostate carcinomas,5 with potential new opportunities for
therapeutic intervention in humans. Evidence suggests that,
despite the high homology between all members of the
HSP90 chaperone family, TRAP1 has distinct functional
properties.6 TRAP1 is involved in endoplasmic reticulum
(ER) stress protection7,8 and some recent findings have
reported other sub-cellular localizations of this chaperone.6 In
fact, we have recently demonstrated that TRAP1 also
localizes in the ER, where it directly interacts with the
proteasomal particle TBP7 and controls ubiquitination/
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A B S T R A C T
TNF receptor-associated protein 1 (TRAP1) is an HSP90 chaperone involved in stress pro-
tection and apoptosis in mitochondrial and extramitochondrial compartments. Remark-
ably, aberrant deregulation of TRAP1 function has been observed in several cancer types
with potential new opportunities for therapeutic intervention in humans. Although pre-
vious studies by our group identified novel roles of TRAP1 in quality control of
mitochondria-destined proteins through the attenuation of protein synthesis, molecular
mechanisms are still largely unknown. To shed further light on the signaling pathways
regulated by TRAP1 in the attenuation of protein synthesis, this study demonstrates
that the entire pathway of cap-mediated translation is activated in cells following
TRAP1 interference: consistently, expression and consequent phosphorylation of
p70S6K and RSK1, two translation activating kinases, are increased upon TRAP1
silencing. Furthermore, we show that these regulatory functions affect the response to
translational stress and cell migration in wound healing assays, processes involving
both kinases. Notably, the regulatory mechanisms controlled by TRAP1 are conserved
in colorectal cancer tissues, since an inverse correlation between TRAP1 and p70S6K
expression is found in tumor tissues, thereby supporting the relevant role of TRAP1 trans-
lational regulation in vivo. Taken as a whole, these new findings candidate TRAP1
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Cellmotility is a highly dynamic phenomenon that is essential to physiological processes such asmorphogenesis,
wound healing and immune response, but also involved in pathological conditions such asmetastatic dissemina-
tion of cancers. The involvement of the molecular chaperone TRAP1 in the regulation of cell motility, although
still controversial, has been recently investigated alongwith somewell-characterized roles in cancer cell survival
and drug resistance in several tumour types. Among different functions, TRAP1-dependent regulation of protein
synthesis seems to be involved in the migratory behaviour of cancer cells and, interestingly, the expression of
p70S6K, a kinase responsible for translation initiation, playing a role in cell motility, is regulated by TRAP1. In
this study, we demonstrate that TRAP1 silencing enhances cell motility in vitro but compromises the ability of
cells to overcome stress conditions, and that this effect is mediated by the AKT/p70S6K pathway. In fact:
i) inhibition of p70S6K activity speciﬁcally reducesmigration in TRAP1 knock-down cells; ii) nutrient deprivation
affects p70S6K activity thereby impairing cellmigration only in TRAP1-deﬁcient cells; iii) TRAP1 regulates the ex-
pression of both AKT and p70S6K at post-transcriptional level; and iii) TRAP1 silencingmodulates the expression
of genes involved in cell motility and epithelial–mesenchymal transition. Notably, a correlation between TRAP1
and AKT expression is found in vivo in human colorectal tumours. These results provide new insights into TRAP1
role in the regulation of cell migration in cancer cells, tumour progression and metastatic mechanisms.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
TRAP1 (Tumour Necrosis Factor Receptor-Associated Protein 1) is a
molecular chaperone, member of the HSP90 family, that contributes to
survival of cancer cells and is induced in most tumour types [1]. Recent
reports have shown that TRAP1 stays at the crossroad ofmultiple crucial
processes in the onset and progression of the malignant phenotype.
Indeed, TRAP1: i) controls protein homeostasis through a direct
involvement in the regulation of protein synthesis and protein co-
translational degradation [2]; ii) contributes to tumour cell bioenergetic
regulation through the control of mitochondrial respiratory complexes
[3–5]; iii) is part of a pro-survival signalling pathway aimed at evading
the toxic effects of oxidants and anticancer drugs and protects mito-
chondria against damaging stimuli via a decrease of ROS generation
[6]. Since elevated ROS are reported to stimulate cell invasion [7],
Yoshida and colleagues [4] evaluated whether TRAP1 expression
might affect this phenotype by transwellmigration assays. Interestingly,
they demonstrated that TRAP1 knockout or transient suppression dra-
matically enhances cell invasiveness, both in mouse ﬁbroblasts and in
a variety of human cell lines. The authors hypothesize that the contribu-
tion of TRAP1 to this phenotypemay be attributed, at least in part, to its
impact on cellular bioenergetics. By contrast, TRAP1-directed tumour
cell metabolism has been proposed as a pivotal mediator of tumour
cell motility and invasion in conditions of nutrient withdrawal [8]. In
this view, mitochondrial HSP90-directed bioenergetics could represent
an adaptive mechanism overcoming the global tumour-suppressive
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